Journal ArticleCirculation · July 23, 2024
For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 23, 2024
BACKGROUND: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased ...
Full textLink to itemCite
Journal ArticleCirculation · July 16, 2024
BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based m ...
Full textLink to itemCite
Journal ArticleAdv Ther · July 2024
INTRODUCTION: Limited data on atrial fibrillation (AF) are available from the Middle East and North Africa region (MENA). The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of patient ...
Full textLink to itemCite
Journal ArticleAm J Med · June 12, 2024
OBJECTIVE: We aimed to evaluate the safety and efficacy of antithrombotic strategies by age in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention in AUGUSTUS. METHODS: Patients were stratified into 3 age ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 4, 2024
BACKGROUND: The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. OBJ ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · June 2024
PURPOSE OF REVIEW: Polyvascular disease has a significant global burden and is associated with increased risk of major adverse cardiac events with each additional vascular territory involved. The purpose of this review is to highlight the risk factors, ass ...
Full textLink to itemCite
Journal ArticleCirculation · May 21, 2024
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empaglif ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · May 18, 2024
Therapeutic anticoagulation showed inconsistent results in hospitalized patients with COVID-19 and selection of the best patients to use this strategy still a challenge balancing the risk of thrombotic and hemorrhagic outcomes. The present post-hoc analysi ...
Full textLink to itemCite
Journal ArticleN Engl J Med · May 2, 2024
BACKGROUND: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk o ...
Full textLink to itemCite
Journal ArticleJ Card Fail · May 2024
BACKGROUND: Heart failure (HF), a common cause of hospitalization, is associated with poor short-term clinical outcomes. Little is known about the long-term prognoses of patients with HF in Latin America. METHODS: BREATHE was the first nationwide prospecti ...
Full textLink to itemCite
Journal ArticleJ Am Soc Nephrol · May 1, 2024
KEY POINTS: Patients with CKD face meaningful risk of heart failure hospitalization. Daprodustat compared with darbepoetin was associated with a nonsignificantly greater number of heart failure hospitalizations in non-dialysis patients. BACKGROUND: Patient ...
Full textLink to itemCite
Journal ArticleEur Heart J Digit Health · May 2024
AIMS: The accuracy of voice-assisted technologies, such as Amazon Alexa, to collect data in patients who are older or have heart failure (HF) is unknown. The aim of this study is to analyse the impact of increasing age and comorbid HF, when compared with y ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2024
AIMS: Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individua ...
Full textLink to itemCite
Journal ArticleN Engl J Med · April 25, 2024
BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who ...
Full textLink to itemCite
Journal ArticleEur J Intern Med · April 19, 2024
INTRODUCTION: Several interventions have been tested for cardio-protection against anthracycline-induced cancer therapy-related cardiovascular dysfunction (CTRCD). The role of statins in this setting remains unclear. METHODS: We systematically searched Pub ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · April 2, 2024
BACKGROUND: BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve p ...
Full textLink to itemCite
Journal ArticleCirculation · July 23, 2024
For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) has been the only class I recommendation on DAPT in American and European guidelines, which has resulted in 12-month durations of DAPT therapy being the most ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 23, 2024
BACKGROUND: ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased ...
Full textLink to itemCite
Journal ArticleCirculation · July 16, 2024
BACKGROUND: Results from the COORDINATE-Diabetes trial (Coordinating Cardiology Clinics Randomized Trial of Interventions to Improve Outcomes - Diabetes) demonstrated that a multifaceted, clinic-based intervention increased prescription of evidence-based m ...
Full textLink to itemCite
Journal ArticleAdv Ther · July 2024
INTRODUCTION: Limited data on atrial fibrillation (AF) are available from the Middle East and North Africa region (MENA). The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patterns, and clinical and economic outcomes of patient ...
Full textLink to itemCite
Journal ArticleAm J Med · June 12, 2024
OBJECTIVE: We aimed to evaluate the safety and efficacy of antithrombotic strategies by age in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention in AUGUSTUS. METHODS: Patients were stratified into 3 age ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 4, 2024
BACKGROUND: The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. OBJ ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · June 2024
PURPOSE OF REVIEW: Polyvascular disease has a significant global burden and is associated with increased risk of major adverse cardiac events with each additional vascular territory involved. The purpose of this review is to highlight the risk factors, ass ...
Full textLink to itemCite
Journal ArticleCirculation · May 21, 2024
BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empaglif ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · May 18, 2024
Therapeutic anticoagulation showed inconsistent results in hospitalized patients with COVID-19 and selection of the best patients to use this strategy still a challenge balancing the risk of thrombotic and hemorrhagic outcomes. The present post-hoc analysi ...
Full textLink to itemCite
Journal ArticleN Engl J Med · May 2, 2024
BACKGROUND: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk o ...
Full textLink to itemCite
Journal ArticleJ Card Fail · May 2024
BACKGROUND: Heart failure (HF), a common cause of hospitalization, is associated with poor short-term clinical outcomes. Little is known about the long-term prognoses of patients with HF in Latin America. METHODS: BREATHE was the first nationwide prospecti ...
Full textLink to itemCite
Journal ArticleJ Am Soc Nephrol · May 1, 2024
KEY POINTS: Patients with CKD face meaningful risk of heart failure hospitalization. Daprodustat compared with darbepoetin was associated with a nonsignificantly greater number of heart failure hospitalizations in non-dialysis patients. BACKGROUND: Patient ...
Full textLink to itemCite
Journal ArticleEur Heart J Digit Health · May 2024
AIMS: The accuracy of voice-assisted technologies, such as Amazon Alexa, to collect data in patients who are older or have heart failure (HF) is unknown. The aim of this study is to analyse the impact of increasing age and comorbid HF, when compared with y ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2024
AIMS: Type 2 diabetes (T2D) is a risk factor for cardiovascular and non-cardiovascular mortality. However, global distribution of cause-specific deaths in T2D is poorly understood. We characterized cause-specific deaths by geographic region among individua ...
Full textLink to itemCite
Journal ArticleN Engl J Med · April 25, 2024
BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who ...
Full textLink to itemCite
Journal ArticleEur J Intern Med · April 19, 2024
INTRODUCTION: Several interventions have been tested for cardio-protection against anthracycline-induced cancer therapy-related cardiovascular dysfunction (CTRCD). The role of statins in this setting remains unclear. METHODS: We systematically searched Pub ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · April 2, 2024
BACKGROUND: BMP10 (bone morphogenic protein 10) has emerged as a novel biomarker associated with the risk of ischemic stroke and other outcomes in patients with atrial fibrillation (AF). The study aimed to determine if repeated BMP10 measurements improve p ...
Full textLink to itemCite
Journal ArticleChest · April 2024
BACKGROUND: Therapeutic-dose heparin decreased days requiring organ support in noncritically ill patients hospitalized for COVID-19, but its impact on persistent symptoms or quality of life (QOL) is unclear. RESEARCH QUESTION: In the Accelerating COVID-19 ...
Full textLink to itemCite
Journal ArticleDiabetes Obes Metab · April 2024
AIMS: To estimate the incidence of a major adverse cardiovascular event (MACE) and a composite kidney outcome across estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) levels, and to determine whether efpeglenatide's e ...
Full textLink to itemCite
Journal ArticleCirculation · March 26, 2024
BACKGROUND: Device-detected atrial fibrillation (also known as subclinical atrial fibrillation or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke ...
Full textLink to itemCite
Journal ArticleRevista da Sociedade de Cardiologia do Estado de São Paulo · March 10, 2024
A detecção de fibrilação atrial (FA) subclínica é um achado frequente em portadores de dispositivos cardíacos eletrônicos implantáveis e associa-se a um risco aumentado de acidente vascular cerebral (AVC). O estudo ARTESiA, publicado em 2023, teve ...
Full textCite
Journal ArticleJ Am Heart Assoc · March 5, 2024
BACKGROUND: Women with chronic coronary disease are generally older than men and have more comorbidities but less atherosclerosis. We explored sex differences in revascularization, guideline-directed medical therapy, and outcomes among patients with chroni ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · January 25, 2024
AIMS: Large outcome trials have demonstrated cardiovascular benefits of selected glucagon-like peptide-1 (GLP-1) receptor agonists. We examined coronary disease outcomes in the Harmony Outcomes trial of the GLP-1 receptor agonist albiglutide. METHODS AND R ...
Full textLink to itemCite
Journal ArticleN Engl J Med · December 28, 2023
BACKGROUND: A strategy of administering a transfusion only when the hemoglobin level falls below 7 or 8 g per deciliter has been widely adopted. However, patients with acute myocardial infarction may benefit from a higher hemoglobin level. METHODS: In this ...
Full textLink to itemCite
Journal ArticleJ Card Fail · December 2023
BACKGROUND: Heart failure (HF) may complicate acute coronary syndrome (ACS) and is associated with a high burden of short- and long-term morbidity and mortality. Only limited data regarding future ischemic events and rehospitalization are available for pat ...
Full textLink to itemCite
Journal ArticleEur Heart J Acute Cardiovasc Care · November 16, 2023
AIMS: Chest pain is a major cause of medical evaluation at emergency department (ED) and demands observation to exclude the diagnosis of acute myocardial infarction (AMI). High-sensitivity cardiac troponin assays used as isolated measure and by 0- and 1-h ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · November 7, 2023
BACKGROUND: The SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) and SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2023
Rate control is fundamental in the treatment of patients with atrial fibrillation (AF). The independent association of heart rate with outcomes and range of heart rate associated with best outcomes remains uncertain. We assessed the relationship between he ...
Full textLink to itemCite
ConferenceAm Heart J · October 2023
BACKGROUND: It is estimated that atrial fibrillation (AF) affects approximately 1.5 million people in Brazil; however, epidemiological data are limited. We sought to evaluate the characteristics, treatment patterns, and clinical outcomes in patients with A ...
Full textLink to itemCite
Journal ArticleJournal of cardiac failure · October 2023
BackgroundVoice-assisted artificial intelligence-based systems may streamline clinical care among patients with heart failure (HF) and caregivers; however, randomized clinical trials are needed. We evaluated the potential for Amazon Alexa (Alexa), ...
Full textCite
Journal ArticleThromb Res · October 2023
BACKGROUND: Antithrombotic treatment may improve the disease course in non-critically ill, symptomatic COVID-19 outpatients. METHODS: We performed an individual patient-level analysis of the OVID and ETHIC randomized controlled trials, which compared enoxa ...
Full textLink to itemCite
Journal ArticleJACC CardioOncol · October 2023
BACKGROUND: Androgen deprivation therapy is the cornerstone of treatment for patients with advanced prostate cancer. Meta-analysis of small, oncology-focused trials suggest gonadotropin-releasing hormone (GnRH) antagonists may be associated with fewer adve ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · September 19, 2023
BACKGROUND: Anatomic complete revascularization (ACR) and functional complete revascularization (FCR) have been associated with reduced death and myocardial infarction (MI) in some prior studies. The impact of complete revascularization (CR) in patients un ...
Full textLink to itemCite
Journal ArticleCurr Probl Cardiol · August 2023
Recent studies focusing on the prevalence, characteristics, and outcomes of primary heart failure (HF) with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF) in non-alcoholic fatty liver disease (NAFLD) are sparse. We sought to asse ...
Full textLink to itemCite
Journal ArticleLancet Reg Health Am · August 2023
BACKGROUND: In patients at high risk of thromboembolism who were discharged after hospitalisation due to COVID-19, thromboprophylaxis with rivaroxaban 10 mg/day for 35 days significantly improved clinical outcomes, reducing thrombotic events compared with ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · August 2023
BACKGROUND: Approximately 25% of patients admitted to hospitals for worsening heart failure (WHF) are readmitted within 30 days. OBJECTIVES: The authors conducted a post hoc analysis of the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in P ...
Full textLink to itemCite
Journal ArticleCochrane Database Syst Rev · July 20, 2023
BACKGROUND: Lower extremity atherosclerotic disease (LEAD) - also known as peripheral arterial disease - refers to the obstruction or narrowing of the large arteries of the lower limbs, most commonly caused by atheromatous plaque. Although in many cases of ...
Full textLink to itemCite
Journal ArticleEuroIntervention · July 17, 2023
Dual antiplatelet therapy (DAPT) is currently the standard of care after percutaneous coronary intervention (PCI). Recent studies suggest that reducing DAPT to 1-3 months followed by an aspirin-free single antiplatelet therapy (SAPT) strategy with a potent ...
Full textLink to itemCite
Journal ArticleEuropace · July 4, 2023
AIMS: Several biomarkers are associated with clinical outcomes in patients with atrial fibrillation (AF), but a causal relationship has not been established. This study aimed to evaluate angiopoietin-2, a novel candidate biomarker of endothelial inflammati ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2023
BACKGROUND: Decisions on stroke prevention strategies in patients with atrial fibrillation (AF) depend on the perceived risks of stroke and bleeding with different antithrombotic treatment strategies. The study objectives were to evaluate net clinical outc ...
Full textLink to itemCite
Journal ArticleCirculation · June 20, 2023
Antiplatelet therapy is the mainstay of pharmacologic treatment to prevent thrombotic or ischemic events in patients with coronary artery disease treated with percutaneous coronary intervention and those treated medically for an acute coronary syndrome. Th ...
Full textLink to itemCite
Journal ArticleBMC Cardiovasc Disord · June 15, 2023
BACKGROUND: Pharmacoinvasive strategy is an effective myocardial reperfusion therapy when primary percutaneous coronary intervention (p-PCI) cannot be performed in a timely manner. METHODS: Authors sought to evaluate metrics of care and cardiovascular outc ...
Full textLink to itemCite
Journal ArticleCirculation · June 6, 2023
BACKGROUND: There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction. METHODS: Using the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral ...
Full textLink to itemCite
Journal ArticleMedicine (Baltimore) · June 2, 2023
BACKGROUND: Although the cornerstone treatment for deep vein thrombosis (DVT) remains anticoagulation, clinicians perform stenting or angioplasty (SA) in particular patients. To assess the effects of SA in this setting, we performed a systematic review of ...
Full textLink to itemCite
Journal ArticleKidney Int · June 2023
The ASCEND-NHQ trial evaluated the effects of daprodustat on hemoglobin and the Medical Outcomes Study 36-item Short Form Survey (SF-36) Vitality score (fatigue) in a multicenter, randomized, double-blind, placebo-controlled trial. Adults with chronic kidn ...
Full textLink to itemCite
Journal ArticleEClinicalMedicine · June 2023
BACKGROUND: COVID-19 progression is associated with an increased risk of arterial and venous thrombosis. Randomised trials have demonstrated that anticoagulants reduce the risk of thromboembolism in hospitalised patients with COVID-19, but a benefit of rou ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · May 1, 2023
IMPORTANCE: Platelet activation is a potential therapeutic target in patients with COVID-19. OBJECTIVE: To evaluate the effect of P2Y12 inhibition among critically ill patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This internationa ...
Full textLink to itemCite
Journal ArticleJAMA · April 18, 2023
IMPORTANCE: Evidence-based therapies to reduce atherosclerotic cardiovascular disease risk in adults with type 2 diabetes are underused in clinical practice. OBJECTIVE: To assess the effect of a coordinated, multifaceted intervention of assessment, educati ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · April 10, 2023
AIMS: Optimal duration of dual antiplatelet therapy (DAPT) in patients with concomitant indication to oral anticoagulation (OAC) is still debated. METHODS AND RESULTS: A systematic review was performed on electronic databases to search for randomized contr ...
Full textLink to itemCite
Journal ArticleEur J Cardiothorac Surg · April 3, 2023
OBJECTIVES: We conducted a systematic review and meta-analysis of randomized controlled trials comparing direct oral anticoagulants (DOACs) to vitamin K antagonists (VKAs) in the first 90 days after bioprosthetic valve implantation. METHODS: We systematica ...
Full textLink to itemCite
Journal ArticleLancet Reg Health Am · April 2023
BACKGROUND: Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients. METHODS: REVOLUT ...
Full textLink to itemCite
Journal ArticleCirculation · March 28, 2023
BACKGROUND: In the AMPLITUDE-O (Effect of Efpeglenatide on Cardiovascular Outcomes) cardiovascular outcomes trial, adding either 4 mg or 6 mg weekly of the glucagon-like peptide-1 receptor agonist efpeglenatide to usual care reduced major adverse cardiovas ...
Full textLink to itemCite
Journal ArticleCardiovasc Diabetol · March 28, 2023
BACKGROUND: Estimating cardiovascular (CV) event accrual is important for outcome trial planning. Limited data exist describing event accrual patterns in patients with type 2 diabetes (T2D). We compared apparent CV event accrual patterns with true event ra ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2023
BACKGROUND: Accumulating evidence from clinical trials suggests that a lower (restrictive) hemoglobin threshold (<8 g/dL) for red blood cell (RBC) transfusion, compared with a higher (liberal) threshold (≥10 g/dL) is safe. However, in anemic patients with ...
Full textLink to itemCite
Journal ArticleStroke · March 2023
Atrial fibrillation (AF) is one of the strongest risk factors for ischemic stroke, which is a leading cause of disability and death. Given the aging population, increasing prevalence of AF risk factors, and improved survival in those with cardiovascular di ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · March 2023
BACKGROUND: Previous studies have demonstrated a high risk of arterial and venous thromboembolic events as a consequence of direct viral damage to endothelial cells by SARS-CoV-2 and a procoagulant milieu due to increased biomarkers, such as D-dimer, fibri ...
Full textLink to itemCite
Journal ArticleDermatol Ther (Heidelb) · February 2023
BACKGROUND: Dermatoporosis defines the progressive chronic cutaneous insufficiency syndrome. Stage I is characterized by cutaneous atrophy, senile purpura, and stellate pseudoscars. OBJECTIVE: To assess clinical, histologic, quality of life, and biophysica ...
Full textLink to itemCite
Journal ArticleAnnu Rev Med · January 27, 2023
Shortly after the emergence of coronavirus disease 2019 (COVID-19) in late 2019, clinicians rapidly recognized an apparent association between the disease and both arterial and venous thrombotic complications, which was confirmed in epidemiologic studies. ...
Full textLink to itemCite
Journal ArticleEur Heart J · January 14, 2023
AIMS: Biomarkers specifically related to atrial tissue may increase the understanding of the pathophysiology of atrial fibrillation (AF) and further improve risk prediction in this setting. Bone morphogenetic protein 10 (BMP10) is a protein expressed in th ...
Full textOpen AccessLink to itemCite
Journal ArticleCirculation · January 3, 2023
BACKGROUND: The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) compared an initial invasive versus an initial conservative management strategy for patients with chronic coronary disease and mod ...
Full textLink to itemCite
Journal ArticleThromb Haemost · January 2023
IMPORTANCE: Aortic stenosis is the most common valvular disease, and more than 90% of patients who undergo aortic valve replacement receive a bioprosthetic valve. Yet optimal antithrombotic therapy after bioprosthetic aortic valve replacement remains unce ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · 2023
BACKGROUND: Previous systematic reviews have identified no benefit of hydroxychloroquine and chloroquine in non-hospitalized COVID-19 patients. After publication of these reviews, the results of COPE, the largest randomized trial conducted to date, became ...
Full textLink to itemCite
Journal ArticleRev Soc Bras Med Trop · 2023
BACKGROUND: Cases of coronavirus disease 2019 (COVID-19) requiring hospitalization continue to appear in vulnerable populations, highlighting the importance of novel treatments. The hyperinflammatory response underlies the severity of the disease, and targ ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · 2023
BACKGROUND: The extent of cardiac damage associated with aortic stenosis has important prognostic implications after transcatheter aortic valve replacement (TAVR). However, the role of tricuspid regurgitation (TR) in this clinical setting is still unclear. ...
Full textLink to itemCite
Journal ArticleRev Assoc Med Bras (1992) · 2023
BACKGROUND: Investigation of syncope involves the use of electrophysiological study, particularly in patients with cardiac conduction disorder. There is conflicting evidence about the role of electrophysiological study in patients with Chagas disease. OBJE ...
Full textLink to itemCite
Journal ArticleCirculation · December 6, 2022
BACKGROUND: There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and with atrial fibrillation (AF). METHODS: The RENAL-AF trial (Renal Hemodialysis Patien ...
Full textLink to itemCite
Journal ArticleNat Rev Cardiol · December 2022
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 years, ...
Full textLink to itemCite
Journal ArticleJ Card Fail · December 2022
The overall patient population in contemporary cardiac intensive care units (CICUs) has only increased with respect to patient acuity, complexity, and illness severity. The current population has more cardiac and noncardiac comorbidities, a higher prevalen ...
Full textLink to itemCite
Journal ArticleLancet Respir Med · December 2022
BACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combi ...
Full textLink to itemCite
Journal ArticleLancet Respir Med · December 2022
BACKGROUND: The large number of patients worldwide infected with the SARS-CoV-2 virus has overwhelmed health-care systems globally. The Anti-Coronavirus Therapies (ACT) outpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antith ...
Full textLink to itemCite
Journal ArticleEur Heart J Acute Cardiovasc Care · November 30, 2022
AIMS: High-risk cardiac surgery is commonly complicated by low cardiac output syndrome (LCOS), which is associated with high mortality. There are limited data derived from multi-centre studies with adjudicated endpoints describing factors associated with L ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · November 1, 2022
BACKGROUND: In patients with acute coronary syndrome (ACS), there is residual and variable risk of recurrent ischemic events. OBJECTIVES: This study aimed to develop biomarker-based prediction models for 1-year risk of cardiovascular (CV) death and myocard ...
Full textLink to itemCite
Journal ArticleNephrol Dial Transplant · October 19, 2022
BACKGROUND: Anaemia is common in chronic kidney disease (CKD) and assessment of the risks and benefits of new therapies is important. METHODS: The Anaemia Study in CKD: Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Non-Dialysis (ASCEN ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Transl Res · October 2022
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, heart failure with preser ...
Full textLink to itemCite
Journal ArticleJ Thromb Haemost · October 2022
Despite the emergence of high quality randomized trial data with the use of antithrombotic agents to reduce the risk of thromboembolism, end-organ failure, and possibly mortality in patients with coronavirus disease 2019 (COVID-19), questions still remain ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · September 29, 2022
AIMS: The aim of this study was to systematically assess the effects of antiplatelets on clinical outcomes in patients with atrial fibrillation (AF), treated and not-treated with oral anticoagulation. METHODS AND RESULTS: We searched MEDLINE, Embase, and C ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · September 29, 2022
BACKGROUND: The clinical impact of different prophylactic anticoagulation regimens among hospitalized patients with coronavirus disease 2019 (COVID-19) remains unclear. We pooled evidence from available randomized controlled trials (RCTs) to provide insigh ...
Full textLink to itemCite
Journal ArticleEur Heart J Qual Care Clin Outcomes · September 5, 2022
AIMS: The geographic representation of investigators and participants in heart failure (HF) randomized controlled trials (RCTs) may not reflect the global distribution of disease. We assessed the geographic diversity of RCT leaders and explored association ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2022
BACKGROUND: Morphine is commonly used to relieve pain, anxiety and dyspnea in STEMI but it lowers blood pressure and delays the activity of oral antiplatelet agents. The impact of morphine on clinical outcomes remains unknown. This analysis was performed t ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2022
BACKGROUND: Atrial fibrillation (AF) and heart failure (HF) often coexist. We investigated the prognostic impact of biomarkers on the development of HF and death in patients with AF and different left ventricular systolic function considering the influence ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 1, 2022
Patients with acute coronary syndrome (ACS) are at risk for recurrent adverse events, and multiple reports suggest that this risk is increased in patients with concomitant diabetes mellitus (DM) and peripheral artery disease (PAD). The aim of this article ...
Full textLink to itemCite
Journal ArticleClin J Am Soc Nephrol · September 2022
BACKGROUND AND OBJECTIVES: Daprodustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being investigated for the treatment of anemia of CKD. In this noninferiority trial, we compared daprodustat administered three times weekly with ep ...
Full textLink to itemCite
Journal ArticleCirculation · August 30, 2022
BACKGROUND: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipopro ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 23, 2022
BACKGROUND: Nonadherence to antiplatelet therapy after percutaneous coronary intervention (PCI) is common, even in clinical trials. OBJECTIVES: The purpose of this study was to investigate the impact of nonadherence to study protocol regimens in the MASTER ...
Full textLink to itemCite
Journal ArticleLancet Haematol · August 2022
BACKGROUND: COVID-19 is associated with inflammation and an increased risk of thromboembolic complications. Prophylactic doses of low-molecular-weight heparin have been used in hospitalised and non-critically ill patients with COVID-19. We aimed to evaluat ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · August 2022
BACKGROUND: ISCHEMIA-CKD (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Chronic Kidney Disease) reported an initial invasive treatment strategy did not reduce the risk of death or nonfatal myocardial infarctio ...
Full textLink to itemCite
Journal ArticleEuropace · July 21, 2022
AIMS: There is uncertainty about whether and how to perform screening for atrial fibrillation (AF). To estimate the incidence of previously undetected AF that would be captured using a continuous 14-day ECG monitor and the associated risk of stroke. METHOD ...
Full textLink to itemCite
Journal ArticleCardiovasc Res · July 20, 2022
AIMS: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique, we explored the association between 268 bioma ...
Full textLink to itemCite
Journal ArticleJAMA · July 19, 2022
IMPORTANCE: Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF) but is not consistently improved by any of the current guideline-directed medical therapies. OBJECTIVE: To determine whether omecamtiv mecar ...
Full textLink to itemCite
ConferenceAm J Med · July 2022
BACKGROUND: Using data from the ODYSSEY OUTCOMES trial (NCT01663402), we sought to identify factors associated with the development of incident atrial fibrillation in patients with recent acute coronary syndrome without prior atrial fibrillation and to det ...
Full textLink to itemCite
Journal ArticleLancet Reg Health Am · July 2022
BACKGROUND: Previous Randomised controlled trials (RCT) evaluating chloroquine and hydroxychloroquine in non-hospitalised COVID-19 patients have found no significant difference in hospitalisation rates. However, low statistical power precluded definitive a ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2022
BACKGROUND: We explored the effect of discontinuing versus continuing angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on clinical outcomes in patients with COVID-19 according to baseline disease severity. METHOD ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2022
BACKGROUND: Screening for atrial fibrillation (AF) is attractive because AF independently raises the risk of ischemic stroke, this risk is largely reversible by long-term oral anticoagulant therapy (OAC), and many patients with AF remain undiagnosed and un ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · July 1, 2022
IMPORTANCE: Data are limited regarding the risk of cerebrovascular ischemic events and major bleeding in patients with atrial fibrillation (AF) and recent acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). OBJECTIVE: Determine t ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · July 1, 2022
IMPORTANCE: Dose-reduced regimens of direct oral anticoagulants (DOACs) may be used for 2 main purposes: dose-adjusted treatment intended as full-intensity anticoagulation (eg, for stroke prevention in atrial fibrillation [AF] in patients requiring dose re ...
Full textLink to itemCite
Journal ArticleClin Cardiol · July 2022
BACKGROUND: Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) assessed the cardiovascular (CV) safety of sitagliptin versus placebo on CV outcomes in patients with type 2 diabetes and CV disease and found sitagliptin noninferior to placebo. ...
Full textLink to itemCite
Journal ArticleJ Clin Hypertens (Greenwich) · July 2022
Uncontrolled hypertension has a high prevalence and is related to numerous negative health outcomes. This study aimed to investigate the factors associated with the lack of blood pressure control in hypertensive Brazilians treated in public and private ser ...
Full textLink to itemCite
Journal ArticleJ Clin Med · June 27, 2022
Cardiovascular comorbidities and immune-response dysregulation are associated with COVID-19 severity. We aimed to explore the key immune cell profile and understand its association with disease progression in 156 patients with hypertension that were hospit ...
Full textLink to itemCite
ConferenceAm Heart J · June 2022
BACKGROUND: The International Study of Comparative Health Effectiveness with Medical and Invasive Approaches trial demonstrated no overall difference in the composite primary endpoint and the secondary endpoints of cardiovascular (CV) death/myocardial infa ...
Full textLink to itemCite
Journal ArticleCJC Open · June 2022
BACKGROUND: Effective treatments for COVID-19 are urgently needed, but conducting randomized trials during the pandemic has been challenging. METHODS: The Anti-Coronavirus Therapy (ACT) trials are parallel factorial international trials that aimed to enrol ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2022
BACKGROUND: We describe variables and outcomes associated with peri-operative mechanical circulatory support (MCS) utilization among patients enrolled in the Levosimendan in patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Req ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2022
BACKGROUND: Randomized clinical trials are the gold standard to assess the causal relationship between an intervention and subsequent outcomes, also known as clinical endpoints. In order to limit bias, central clinical events committees (CEC) are establish ...
Full textLink to itemCite
Journal ArticleJAMA Intern Med · June 1, 2022
IMPORTANCE: Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) therapy. Few studies of anemia treatment in an incident dialysis (ID) populat ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · May 5, 2022
AIMS: Whether diabetes without insulin therapy is an independent cardiovascular (CV) risk factor in atrial fibrillation (AF) has recently been questioned. We investigated the prognostic relevance of diabetes with or without insulin treatment in patients in ...
Full textLink to itemCite
Journal ArticleActa Cardiol · May 2022
BACKGROUND AND PURPOSE: Hypertension is common in patients with atrial fibrillation (AF) and carries an additional risk for complications, most notably stroke and bleeding. We assessed the history of hypertension, level of blood pressure control, and an in ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2022
BACKGROUND: Renin-angiotensin aldosterone system inhibitors (RAASi) are commonly used among patients hospitalized with a severe acute respiratory syndrome coronavirus 2 infection coronavirus disease 2019 (COVID-19). We evaluated whether continuation versus ...
Full textLink to itemCite
Journal ArticleKidney360 · April 28, 2022
The coronavirus disease 2019 pandemic has had an unprecedented effect on health and health care and posed challenges to the conduct of clinical trials.Targeted mitigating strategies, on the basis of early and continued data collection from site surveys, li ...
Full textLink to itemCite
Journal ArticleNephrol Dial Transplant · April 25, 2022
BACKGROUND: The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is noninferior to comparator epoetin alfa or darbepoetin ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · April 2022
The optimal INR target in patients with mechanical heart valves is unclear. Higher INR targets are often used in Western compared with East Asian countries. The objective of this systematic review and meta-analysis was to summarize the evidence for the eff ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2022
IMPORTANCE: Clinical events adjudication is pivotal for generating consistent and comparable evidence in clinical trials. The methodology of event adjudication is evolving, but research is needed to develop best practices and spur innovation. OBSERVATIONS: ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · March 2022
BACKGROUND: In randomized trials, cangrelor reduced periprocedural ischemic events related to percutaneous coronary intervention without increasing GUSTO severe bleeding. However, some antiplatelet agents have shown a differential treatment effect by body ...
Full textLink to itemCite
Journal ArticleCirculation · February 22, 2022
BACKGROUND: Both sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists reduce cardiovascular events among patients with type 2 diabetes. However, no cardiovascular outcome trial has evaluated the long-term effects ...
Full textLink to itemCite
Journal ArticleJAMA · February 15, 2022
IMPORTANCE: Acute coronary syndromes (ACS) are characterized by a sudden reduction in blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), and unstable angina. Each year, an estimated more than 7 mil ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · February 8, 2022
BACKGROUND: The use of apixaban instead of vitamin K antagonists (VKA) as well as dropping aspirin results in less bleeding and comparable ischemic events in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary interve ...
Full textLink to itemCite
Journal ArticleCardiovasc Diabetol · February 5, 2022
BACKGROUND: There is uncertainty and limited data regarding initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors among patients hospitalized with acute heart failure (AHF). This systematic review and meta-analysis aim to establish the efficacy a ...
Full textLink to itemCite
Journal ArticleAm J Med · February 2022
BACKGROUND: Patients with atrial fibrillation and bioprosthetic valves are at high risk for thromboembolic events. The pooled efficacy and safety of non-vitamin K oral anticoagulants (NOACs), as a class, relative to warfarin in this population is not well- ...
Full textLink to itemCite
Journal ArticleOpen Heart · February 2022
OBJECTIVE: Managing antithrombotic therapy in patients with atrial fibrillation (AF) and an acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) is challenging and can be affected by prior oral anticoagulant (OAC) treatment. We exa ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · February 1, 2022
IMPORTANCE: Based on contemporary estimates in the US, evidence-based therapies for cardiovascular risk reduction are generally underused among patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). OBJECTIVE: To determine the us ...
Full textLink to itemCite
Journal ArticleEur Heart J Suppl · February 2022
The non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban have transformed the management of atrial fibrillation (AF), but are only approved by regulatory authorities for stroke prophylaxis in patients with so ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · February 2022
BACKGROUND: Despite the need for targeting specific therapeutic options for coronavirus disease 2019 (COVID-19), there has been no evidence of effectiveness of any specific treatment for the outpatient clinical setting. There are few randomized studies eva ...
Full textLink to itemCite
Journal ArticleCirculation · January 25, 2022
BACKGROUND: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. METHODS: We used individual patient dat ...
Full textLink to itemCite
Journal ArticleJAMA · January 25, 2022
IMPORTANCE: Vaccination against COVID-19 provides clear public health benefits, but vaccination also carries potential risks. The risks and outcomes of myocarditis after COVID-19 vaccination are unclear. OBJECTIVE: To describe reports of myocarditis and th ...
Full textLink to itemCite
Journal ArticleJAMA · January 18, 2022
IMPORTANCE: Platelets represent a potential therapeutic target for improved clinical outcomes in patients with COVID-19. OBJECTIVE: To evaluate the benefits and risks of adding a P2Y12 inhibitor to anticoagulant therapy among non-critically ill patients ho ...
Full textOpen AccessLink to itemCite
Journal ArticleEur Heart J Qual Care Clin Outcomes · January 5, 2022
AIMS: Older patients with atrial fibrillation (AF) are at risk of adverse outcomes, which is accentuated by comorbidities. We sought to examine the association between morbidity burden and the treatment of older AF patients. METHODS AND RESULTS: Using Dani ...
Full textLink to itemCite
ConferenceDiabetes Care · January 1, 2022
OBJECTIVE: Phenotypic heterogeneity among patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) is ill defined. We used cluster analysis machine-learning algorithms to identify phenotypes among trial participants ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · January 2022
BACKGROUND: Thrombotic events are reduced with cangrelor, an intravenous P2Y12 inhibitor. We sought to characterize the timing, number, and type of early events (within 2 hours of randomization) in CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to ...
Full textLink to itemCite
Journal ArticleLancet · January 1, 2022
BACKGROUND: Patients hospitalised with COVID-19 are at risk for thrombotic events after discharge; the role of extended thromboprophylaxis in this population is unknown. METHODS: In this open-label, multicentre, randomised trial conducted at 14 centres in ...
Full textLink to itemCite
Journal ArticleClin Appl Thromb Hemost · 2022
BACKGROUND: The COMPASS trial demonstrated that in patients with peripheral arterial disease, the combination of rivaroxaban and aspirin compared with aspirin reduces the risk of major adverse limb events, but it is not known whether this combination can a ...
Full textLink to itemCite
Journal ArticleRev Assoc Med Bras (1992) · January 2022
OBJECTIVE: Risk stratification of sudden cardiac death in patients with coronary artery disease is of great importance. We evaluated the association between ventricular repolarization and induction of malignant ventricular arrhythmias on electrophysiologic ...
Full textLink to itemCite
Journal ArticleRevista Brasileira de Terapia Intensiva · January 1, 2022
Repurposed drugs are important in resource-limited settings because the interventions are more rapidly available, have already been tested safely in other populations and are inexpensive. Repurposed drugs are an effective solution, especially for emerging ...
Full textCite
Journal ArticleRev Bras Ter Intensiva · 2022
Repurposed drugs are important in resource-limited settings because the interventions are more rapidly available, have already been tested safely in other populations and are inexpensive. Repurposed drugs are an effective solution, especially for emerging ...
Full textLink to itemCite
Journal ArticleFront Genet · 2022
Apixaban is a direct oral anticoagulant, a factor Xa inhibitor, used for the prevention of ischemic stroke in patients with atrial fibrillation. Despite using recommended dosing a few patients might still experience bleeding or lack of efficacy that might ...
Full textLink to itemCite
Journal ArticleRev Bras Ter Intensiva · 2022
OBJECTIVE: To compare the lung mechanics and outcomes between COVID-19-associated acute respiratory distress syndrome and non-COVID-19-associated acute respiratory distress syndrome. METHODS: We combined data from two randomized trials in acute respiratory ...
Full textLink to itemCite
Journal ArticleClin Appl Thromb Hemost · 2022
Direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prevention after major gynecological cancer surgery might be an alternative to parenteral low-molecular-weight heparin (LMWH). Patients undergoing major gynecological cancer surgery were r ...
Full textLink to itemCite
Journal ArticleN Engl J Med · December 16, 2021
BACKGROUND: Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. In patients with chronic kidney disease (CKD) who are not undergoing dialysis, the efficacy and safety of daprodustat, as compared with the conventional erythropoiesi ...
Full textLink to itemCite
Journal ArticleN Engl J Med · December 16, 2021
BACKGROUND: Among patients with chronic kidney disease (CKD), the use of recombinant human erythropoietin and its derivatives for the treatment of anemia has been linked to a possibly increased risk of stroke, myocardial infarction, and other adverse event ...
Full textLink to itemCite
Journal ArticleAm Heart J · December 2021
BACKGROUND: The devastating Coronavirus disease (COVID-19) pandemic is associated with a high prothrombotic state. It is unclear if the coagulation abnormalities occur because of the direct effect of SARS-CoV-2 or indirectly by the cytokine storm and endot ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · December 2021
BACKGROUND: Older adults with atrial fibrillation (AF) are often treated with the shortest possible duration of antiplatelet/anticoagulant therapy after myocardial infarction (MI) or percutaneous coronary intervention (PCI) due to concern for bleeding. How ...
Full textLink to itemCite
ConferenceCirculation · November 2021
BackgroundA proportion of patients with embolic stroke of undetermined source have silent atrial fibrillation (AF) or develop AF after the initial evaluation. Better understanding of the risk for development of AF is critical to implement optimal ...
Full textCite
Journal ArticleJ Thromb Haemost · November 2021
BACKGROUND: Although older patients are at increased risk for venous thromboembolism (VTE), thromboprophylaxis is underused because of bleeding concerns. The MARINER trial evaluated whether rivaroxaban reduced symptomatic postdischarge VTE in acutely ill m ...
Full textLink to itemCite
Journal ArticleJ Thromb Haemost · November 2021
BACKGROUND: Oral anticoagulants (OAC) in patients with atrial fibrillation (AF) prevent thromboembolic events, but are associated with significant risk of bleeding. OBJECTIVES: To explore associations between a wide range of biomarkers and bleeding risk in ...
Full textLink to itemCite
Journal ArticleCirculation · October 19, 2021
BACKGROUND: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial. METHODS: In this internation ...
Full textLink to itemCite
Journal ArticleCochrane Database of Systematic Reviews · October 13, 2021
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effects of telemedicine for the treatment of foot ulcers in people with diabetes. ...
Full textCite
Journal ArticleCochrane Database Syst Rev · October 12, 2021
BACKGROUND: Arterial vascular access is a frequently performed procedure, with a high possibility for adverse events (e.g. pneumothorax, haemothorax, haematoma, amputation, death), and additional techniques such as ultrasound may be useful for improving ou ...
Full textLink to itemCite
Journal ArticleEur Heart J Acute Cardiovasc Care · October 1, 2021
AIMS: The incidence of respiratory failure and use of invasive or non-invasive mechanical ventilation (MV) in the cardiac intensive care units (CICUs) is increasing. While institutional MV volumes are associated with reduced mortality in medical and surgic ...
Full textLink to itemCite
Journal ArticleInt J Cardiol Heart Vasc · October 2021
BACKGROUND: Patients with Coronavirus Disease 2019 (COVID-19) may present high risk features during hospitalization, including cardiovascular manifestations. However, less is known about the factors that may further increase the risk of death in these pati ...
Full textLink to itemCite
Journal ArticleCurr Heart Fail Rep · October 2021
PURPOSE OF REVIEW: With recent advances in the pharmacological management of type 2 diabetes mellitus (T2DM), there is a growing need to understand which patients optimally benefit from these novel therapies. Various clinical clustering methodologies have ...
Full textLink to itemCite
Journal ArticleLancet Diabetes Endocrinol · October 2021
BACKGROUND: GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. ...
Full textLink to itemCite
Journal ArticleThe New England journal of medicine · September 2021
BackgroundFour glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among persons with type 2 diabetes. The effect of an exendin-based GL ...
Full textCite
Journal ArticleAm Heart J Plus · September 2021
BACKGROUND: Peripheral artery disease (PAD) is associated with an increased risk of ischemic events following percutaneous coronary intervention (PCI). More aggressive antiplatelet therapy may mitigate this risk. The present study evaluates the efficacy of ...
Full textLink to itemCite
Journal ArticleEuropean Heart Journal - Digital Health · September 1, 2021
Aims: Artificial intelligence (A.I) driven voice-based assistants may facilitate data capture in clinical care and trials; however, the feasibility and accuracy of using such devices in a healthcare environment are unknown. We explored the feasibility of u ...
Full textCite
Journal ArticleJ Am Coll Cardiol · August 3, 2021
BACKGROUND: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is unce ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2021
BACKGROUND: Observational studies have suggested a higher risk of thrombotic events in patients with coronavirus disease 2019 (COVID-19). Moreover, elevated D-dimer levels have been identified as an important prognostic marker in COVID-19 directly associat ...
Full textOpen AccessLink to itemCite
Journal ArticleAnn Intern Med · August 2021
BACKGROUND: In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial, sotagliflozin, a sodium-glucose cotransporter-1 and sodium-glucose cotransporter-2 inhibitor, reduced tot ...
Full textLink to itemCite
Journal ArticleCirculation · July 6, 2021
Multiple sodium glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to impart significant cardiovascular and kidney benefits, but are underused in clinical practice. Both SGLT-2i and GLP-1RA ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · July 1, 2021
IMPORTANCE: Randomized clinical trials (RCTs) are critical in advancing patient care, yet conducting such large-scale trials requires tremendous resources and coordination. Clinical site start-up performance metrics can provide insight into opportunities f ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · July 2021
BACKGROUND: Primary percutaneous coronary intervention is considered the "gold standard" for coronary reperfusion. However, when not available, the drug-invasive strategy is an alternative method and the electrocardiogram (ECG) has been used to identify re ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · June 1, 2021
To address literature gaps on treatment with real-world evidence, this study compared effectiveness, safety, and cost outcomes in NVAF patients with coronary or peripheral artery disease (CAD, PAD) prescribed apixaban versus other oral anticoagulants. NVAF ...
Full textLink to itemCite
Journal ArticleLancet (London, England) · June 2021
BackgroundCOVID-19 is associated with a prothrombotic state leading to adverse clinical outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised with COVID-19 is unknown. We aimed to compare the efficacy and safety ...
Full textCite
Journal ArticleCell reports. Medicine · June 2021
Untargeted metabolomics is used to refine the development of biomarkers for the diagnosis of cardiovascular disease. Myocardial infarction (MI) has major individual and societal consequences for patients, who remain at high risk of secondary events, despit ...
Full textCite
Journal ArticleHeart · May 2021
AIMS: The ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial randomised patients with atrial fibrillation at risk of stroke to apixaban or warfarin. We sought to describe patients from ARISTOTLE who pr ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · May 2021
INTRODUCTION: Ventricular arrhythmias (VAs) are a major cause of morbidity and mortality in patients with heart disease. Recent studies evaluated the effect of renal denervation (RDN) on the occurrence of VAs. We conducted a systematic review and meta-anal ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · April 9, 2021
AIMS: Safety and efficacy of antithrombotic regimens in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) may differ based on clinical presentation. We sought to compare double vs. triple antithrombotic therapy (DAT ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · April 2021
OBJECTIVES: The authors estimated changes of stressed blood volume (SBV) induced by splanchnic nerve block (SNB) in patients with either decompensated or ambulatory heart failure with reduced ejection fraction (HFrEF). BACKGROUND: The splanchnic vascular c ...
Full textLink to itemCite
Journal ArticleCirculation · March 23, 2021
BACKGROUND: In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2021
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred class of medications for prevention of stroke and systemic embolism in patients with atrial fibrillation unless contraindications exist. Five large, international, randomize ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2021
In this report, we aim to provide an updated meta-analysis of the sodium-glucose cotransporter 2 (SGLT2) inhibitors trial data with the new trial data on sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor. We searched Medline, Cochrane library, ...
Full textLink to itemCite
Journal ArticleOpen Heart · March 2021
OBJECTIVES: Growth differentiation factor 15 (GDF-15) is a biomarker independently associated with bleeding and death in anticoagulated patients with atrial fibrillation (AF). GDF-15 is also used as one component in the more precise biomarker-based ABC (ag ...
Full textOpen AccessLink to itemCite
Journal ArticleCirculation · February 23, 2021
BACKGROUND: In the ISCHEMIA trial (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches), an initial invasive strategy did not significantly reduce rates of cardiovascular events or all-cause mortality in comparison ...
Full textLink to itemCite
Journal ArticleCirculation · February 9, 2021
A growing number of patients undergoing percutaneous coronary intervention (PCI) with stent implantation also have atrial fibrillation. This poses challenges for their optimal antithrombotic management because patients with atrial fibrillation undergoing P ...
Full textOpen AccessLink to itemCite
Journal ArticleTrials · February 5, 2021
OBJECTIVES: The aim of the RAAS-COVID-19 randomized control trial is to evaluate whether an upfront strategy of temporary discontinuation of renin angiotensin aldosterone system (RAAS) inhibition versus continuation of RAAS inhibition among patients admitt ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2021
UNLABELLED: Morbidity and mortality associated with COVID-19 has increased exponentially, and patients with cardiovascular (CV) disease are at risk for poor outcomes. Several lines of evidence suggest a potential role for CV therapies in COVID-19 treatment ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2021
UNLABELLED: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use is associated with improved cardiovascular and kidney outcomes. However, the magnitude and potential heterogeneity of effect across patients with varying types of cardiometabolic and kidney ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · February 2021
BACKGROUND: The histopathological characteristics of Chagas disease (ChD) are: presence of myocarditis, destruction of heart fibers, and myocardial fibrosis. Galectin-3 (Gal-3) is a biomarker involved in the mechanism of fibrosis and inflammation that may ...
Full textLink to itemCite
Journal ArticleCirculation · January 26, 2021
Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected un ...
Full textLink to itemCite
Journal ArticleBMJ · January 20, 2021
OBJECTIVE: To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19). DESIGN: Randomised, open label trial. SETTING: Nine hospitals in Brazil, 8 May to 17 July 2020. PARTICIPANTS: A ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · January 19, 2021
Background Evidence-based therapies are generally underused for cardiovascular risk reduction; however, less is known about contemporary patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Methods and Results Pharmacy and med ...
Full textLink to itemCite
Journal ArticleJAMA · January 19, 2021
IMPORTANCE: It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). OBJECTIVE: ...
Full textLink to itemCite
Journal ArticleCochrane Database of Systematic Reviews · January 19, 2021
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effects of duplex ultrasound versus pulse palpation, arterial pressure index, angiography, or any combination of these, for surveillance of l ...
Full textCite
Journal ArticleN Engl J Med · January 14, 2021
BACKGROUND: The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is unknown. METHODS: We randomly assigne ...
Full textLink to itemCite
Journal ArticleN Engl J Med · January 14, 2021
BACKGROUND: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied. METHODS ...
Full textLink to itemCite
Journal ArticleN Engl J Med · January 14, 2021
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initi ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2021
The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain. DESIGN: RIVER was an academic-led, multicenter, open-label, randomized, non-inferiority trial with blinded outcome adju ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2021
OBJECTIVES: We aimed to evaluate the association between levosimendan treatment and acute kidney injury (AKI) as well as assess the clinical sequelae of AKI in cardiac surgery patients with depressed left ventricular function (ejection fraction <35%). METH ...
Full textLink to itemCite
Journal ArticleProg Cardiovasc Dis · 2021
Background The role of late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (c-MRI) for predicting outcomes of patients with hypertrophic cardiomyopathy (HCM) has been debated. Methods We searched PubMed and Embase and various published ...
Full textLink to itemCite
Journal ArticleIndian Pacing Electrophysiol J · 2021
INTRODUCTION: Electrical pulmonary vein isolation (PVI) is used for the invasive treatment of atrial fibrillation (AF). However, despite the procedure's technical evolution, the rate of AF recurrence due to electrical reconnection of the PVs is high. The a ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · January 2021
BACKGROUND: In clinical practice, there is evidence of failure to prescribe evidence-based therapies for patients at high cardiovascular risk. However, in Brazil, data on 1-year outcomes of these patients remain insufficient. OBJECTIVES: To describe the us ...
Full textLink to itemCite
Journal ArticleTH Open · January 2021
Introduction The risk of venous thromboembolism (VTE) increases during pregnancy and the puerperium such that VTE is a leading cause of maternal mortality. Methods We describe the clinical characteristics, diagnostic strategies, treatment patterns, and o ...
Full textLink to itemCite
Journal ArticleRev Bras Ter Intensiva · 2021
INTRODUCTION: The long-term effects caused by COVID-19 are unknown. The present study aims to assess factors associated with health-related quality of life and long-term outcomes among survivors of hospitalization for COVID-19 in Brazil. METHODS: This is a ...
Full textLink to itemCite
Journal ArticleFront Cardiovasc Med · 2021
Background: Cardiovascular comorbidities such as hypertension and inflammatory response dysregulation are associated with worse COVID-19 prognoses. Different cytokines have been proposed to play vital pathophysiological roles in COVID-19 progression, but a ...
Full textLink to itemCite
Journal ArticleProg Cardiovasc Dis · 2021
Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel forms the backbone of secondary prevention in patients with acute coronary syndromes (ACS) or who undergo percutaneous coronary intervention (PCI), but in patients with atrial fibrillation (AF) ...
Full textLink to itemCite
Journal ArticleTelemed Rep · 2021
Background: Different approaches of evaluation by cardiologists using telemedicine have the potential of improving care of patients with ST elevation myocardial infarction (STEMI). Objective: To compare the use of pharmacoinvasive strategy and associated c ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 15, 2020
Background To explore the pathophysiological features of ischemic stroke in patients with atrial fibrillation (AF), we evaluated the association between 268 plasma proteins and subsequent ischemic stroke in 2 large AF cohorts receiving oral anticoagulation ...
Full textOpen AccessLink to itemCite
Journal ArticleEur J Intern Med · December 2020
AIM: A variety of consumer-facing wearables, devices and apps are marketed directly to consumers to detect atrial fibrillation (AF). However, their management is not defined. Our aim was to explore their role for AF screening via a survey. METHODS AND RESU ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 2020
Background Knowledge is scarce regarding how multimorbidity is associated with therapeutic decisions regarding oral anticoagulants (OACs) in patients with atrial fibrillation. Methods and Results We conducted a cross-sectional study of hospitalized patient ...
Full textOpen AccessLink to itemCite
Journal ArticleN Engl J Med · November 26, 2020
BACKGROUND: The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS: In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target international n ...
Full textLink to itemCite
Journal ArticleN Engl J Med · November 19, 2020
BACKGROUND: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. METHODS: We conducted a multicenter, randomized, open-lab ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · November 15, 2020
BACKGROUND: This review assessed global health technology assessment (HTA) reports and recommendations of non-vitamin K oral anticoagulants (NOACs) in non-valvular atrial fibrillation (NVAF). METHODS: NHTA agency websites were searched for HTA reports eval ...
Full textLink to itemCite
Journal ArticleCirculation · November 3, 2020
BACKGROUND: Whether an initial invasive strategy in patients with stable ischemic heart disease and at least moderate ischemia improves outcomes in the setting of a history of heart failure (HF) or left ventricular dysfunction (LVD) when ejection fraction ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2020
UNLABELLED: The use of cardiac magnetic resonance imaging (c-MRI) in risk stratification for clinical outcomes of patients with ischemic cardiomyopathy (ICM) remains low. This systematic review investigated the prognostic value of myocardial fibrosis as as ...
Full textLink to itemCite
Journal ArticleEur Heart J · November 1, 2020
AIMS: The global COVID-19 pandemic is caused by the SARS-CoV-2 virus entering human cells using angiotensin-converting enzyme 2 (ACE2) as a cell surface receptor. ACE2 is shed to the circulation, and a higher plasma level of soluble ACE2 (sACE2) might refl ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · November 2020
BACKGROUND: Peripheral artery disease is common and associated with high mortality. There are limited data detailing causes of death among patients with peripheral artery disease. METHODS: EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) w ...
Full textLink to itemCite
Journal ArticleJAMA · October 6, 2020
IMPORTANCE: Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients. OBJECTIVE: To dete ...
Full textLink to itemCite
Journal ArticleLancet · October 3, 2020
BACKGROUND: The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the h ...
Full textLink to itemCite
Journal ArticleAm J Med · October 2020
There were 33,269 apixaban-warfarin, 9,345 dabigatran-warfarin, and 42,156 rivaroxaban-warfarin matched pairs, with a median follow-up of 4-5 months. Compared with warfarin, apixaban was associated with lower rates of stroke/systemic embolism (hazard ratio ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2020
BACKGROUND: The optimal role of radial artery grafts in coronary artery bypass grafting (CABG) remains uncertain. The purpose of this study was to examine angiographic and clinical outcomes following CABG among patients who received a radial artery graft. ...
Full textLink to itemCite
Journal ArticleBraz J Cardiovasc Surg · October 1, 2020
OBJECTIVE: To describe insulin use and postoperative glucose control in patients undergoing coronary artery bypass graft (CABG) surgery. METHODS: We examined 2,390 patients with and without diabetes enrolled in the Contemporary Analysis of Perioperative Ca ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · September 15, 2020
Background We compared different methods of estimated glomerular filtration rate (eGFR) and their association with cardiovascular death and major bleeding in 14 980 patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Ot ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Thromb Haemost · September 2020
BACKGROUND: The inflammatory biomarker interleukin-6 (IL-6) is associated with mortality in atrial fibrillation (AF). OBJECTIVE: To investigate if repeated IL-6 measurements improve the prognostication for stroke or systemic embolism, major bleeding, and m ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Med (Hagerstown) · September 2020
BACKGROUND: Atrial fibrillation is the most common cardiac arrhythmia, affecting 33.5 million patients globally. It is associated with increased morbidity, leading to significant clinical and economic burden. There exist only limited data in the Middle Eas ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2020
Vitamin K antagonists are the only approved oral anticoagulants for long-term prophylaxis against valve thrombosis and thromboembolism in patients with a mechanical heart valve. Despite the proven efficacy and safety of anticoagulation with the oral direct ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2020
BACKGROUND: New antithrombotic strategies that reduce primary thrombosis and restenosis might improve vascular outcomes in patients with peripheral artery disease (PAD) undergoing arterial angioplasty. The study objective is to evaluate the potential benef ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · September 1, 2020
IMPORTANCE: Most patients with atrial fibrillation (AF) and coronary artery disease have indications for preventing stroke with oral anticoagulation therapy and preventing myocardial infarction and stent thrombosis with platelet inhibition. OBJECTIVE: To e ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 18, 2020
Background The optimal antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention is a topic of debate. We aimed at defining the efficacy and safety of double antithrombotic therapy with single antiplatelet t ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 4, 2020
Concerns about the external validity of traditional randomized clinical trials (RCTs), together with the widespread availability of real-world data and advanced data analytic tools, have led to claims that common sense and clinical observation, rather than ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Cardiovasc Transl Res · August 2020
Volume management is an essential component of anti-hypertensive therapy. Different volume phenotypes have been proposed. We sought to study the total blood volume (TBV), plasma volume (PV), and red blood cell volume (RBV) in hypertensive patients. We incl ...
Full textLink to itemCite
Journal ArticleCatheter Cardiovasc Interv · August 2020
BACKGROUND: Prior randomized controlled trials (RCT) evaluating the optimal antithrombotic therapies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) have not been powered to evaluate ischemic outcomes. We comp ...
Full textLink to itemCite
Journal ArticleEur J Prev Cardiol · August 2020
BACKGROUND: A novel approach to determine the effect of a treatment is to calculate the delay of event, which estimates the gain of event-free time. The aim of this study was to estimate gains in event-free time for stroke or systemic embolism, death, blee ...
Full textLink to itemCite
Journal ArticleJ Intern Med · August 2020
BACKGROUND: Cardiac troponin T (cTnT) and I (cTnI) concentrations provide strong prognostic information in anticoagulated patients with atrial fibrillation (AF). Whether the associations between cardiac troponin concentrations and mortality and morbidity d ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · August 1, 2020
This study investigates the association between timing of mechanical ventilation initiation and mortality in patients with refractory cardiogenic shock. ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2020
UNLABELLED: Clinical guideline documents reflect the evidence supporting clinical practice, but few recommendations in cardiovascular guidelines are supported by evidence from randomized controlled trials (RCTs), the highest level of evidence. Incentives f ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2020
Angiotensin-converting enzyme-2 (ACE2) expression may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs). Because renin-angiotensin system blockers increase levels of ACE2 ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 14, 2020
BACKGROUND: The long-term prognostic impact of post-discharge bleeding in the unique population of patients with acute coronary syndrome (ACS) treated without percutaneous coronary intervention (PCI) remains unexplored. OBJECTIVES: The aim of this study wa ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · July 1, 2020
IMPORTANCE: While many features of stable ischemic heart disease vary by sex, differences in ischemia, coronary anatomy, and symptoms by sex have not been investigated among patients with moderate or severe ischemia. The enrolled ISCHEMIA trial cohort that ...
Full textLink to itemCite
Journal ArticleCurr Hypertens Rep · June 13, 2020
PURPOSE OF REVIEW: There is increasing evidence indicating an association between several risk factors and worse prognosis in patients with coronavirus disease 2019 (COVID-19), including older age, hypertension, heart failure, diabetes, and pulmonary disea ...
Full textLink to itemCite
Journal ArticleJ Thorac Cardiovasc Surg · June 2020
OBJECTIVE: In the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial, no differences in clinical outcomes were observed between levosimendan and placebo in a broa ...
Full textLink to itemCite
Journal ArticleEur J Intern Med · June 2020
BACKGROUND: The decision on whether non-ST-segment elevation myocardial infarction (NSTEMI) patients should be admitted to intensive care units (ICU) takes into account several factors including hospital routines. The Acute Coronary Treatment and Intervent ...
Full textLink to itemCite
Journal ArticleCirculation · May 19, 2020
BACKGROUND: In AUGUSTUS (Open-Label, 2×2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Perc ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 13, 2020
Background: Angiotensin-converting enzyme-2 (ACE2) may increase due to upregulation in patients using angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB). Because renin-angiotensin system blockers increase levels of ACE2 ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Am Coll Cardiol · May 12, 2020
BACKGROUND: Cholesterol reduction with proprotein convertase subtilisin-kexin type 9 inhibitors reduces ischemic events; however, the cost-effectiveness in statin-treated patients with recent acute coronary syndrome remains uncertain. OBJECTIVES: This stud ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · May 1, 2020
IMPORTANCE: Antithrombotic treatment in patients with atrial fibrillation (AF) and percutaneous coronary intervention (PCI) presents a balancing act with regard to bleeding and ischemic risks. OBJECTIVES: To evaluate the safety and efficacy of 4 antithromb ...
Full textLink to itemCite
Journal ArticleEuropace · May 1, 2020
The field of observational studies or "real world studies" is in rapid development with many new techniques introduced and increased understanding of traditional methods. For this reason the current paper provides an overview of current methods with focus ...
Full textLink to itemCite
Journal ArticleCirculation · April 28, 2020
BACKGROUND: Compared with the general population, patients with advanced chronic kidney disease have a >10-fold higher burden of atrial fibrillation. Limited data are available guiding the use of nonvitamin K antagonist oral anticoagulants in this populati ...
Full textLink to itemCite
Journal ArticleCochrane Database of Systematic Reviews · April 17, 2020
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess the effects of ultrasound guidance for arterial (other than femoral) catheterisation in adults. ...
Full textCite
Journal ArticleN Engl J Med · April 9, 2020
BACKGROUND: Among patients with stable coronary disease and moderate or severe ischemia, whether clinical outcomes are better in those who receive an invasive intervention plus medical therapy than in those who receive medical therapy alone is uncertain. M ...
Full textLink to itemCite
Journal ArticleTrials · April 9, 2020
BACKGROUND: The primary goal of phase 2 and 3 clinical trials is to evaluate the safety and effectiveness of therapeutic interventions, and efficient and reproducible ascertainment of important clinical events, either as clinical outcome events (COEs) or a ...
Full textLink to itemCite
Journal ArticleNat Rev Cardiol · April 2020
Advances in antiplatelet therapies for patients with cardiovascular disease have improved patient outcomes over time, but the challenge of balancing the risks of ischaemia and bleeding remains substantial. Moreover, many patients with cardiovascular diseas ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 17, 2020
BACKGROUND: In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial, patients with atrial fibrillation and ≥2 dose-adjustment criteria (age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dl [133 μmo ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2020
OBJECTIVES: A history of gastrointestinal bleeding (GIB) in patients with atrial fibrillation (AF) may impact decisions about anticoagulation treatment. We sought to determine whether prior GIB in patients with AF taking anticoagulants was associated with ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · March 1, 2020
BACKGROUND: Variation in patient characteristics and practice patterns may influence outcomes at a regional level. METHODS: We assessed differences in demographics, practice patterns, outcomes, and the effect of apixaban compared with warfarin in ARISTOTLE ...
Full textLink to itemCite
Journal ArticleThromb Haemost · March 2020
BACKGROUND: Western guidelines recommend an international normalized ratio (INR) range of 2 to 3 when using warfarin for stroke prevention in atrial fibrillation (AF), but lower INR ranges are frequently used in East Asia. We performed a systematic review ...
Full textLink to itemCite
Journal ArticleJournal of thrombosis and thrombolysis · February 2020
Acutely ill medical patients with cancer are at increased risk of venous thromboembolism (VTE). Thromboprophylaxis is recommended in the presence of cancer, but its safety is not known. The aim of this study was to assess the efficacy and safety of extende ...
Full textCite
Journal ArticleObes Surg · February 2020
OBJECTIVE: The aim of this study was to examine echocardiographic parameters of left ventricle (LV) mechanics in obese patients before and after sleeve gastrectomy (SG). DESIGN AND METHODS: Twenty-five obese individuals submitted to laparoscopic SG were en ...
Full textLink to itemCite
Journal ArticleDiabetes Care · February 2020
OBJECTIVE: To evaluate the impact of once-weekly exenatide (EQW) on microvascular and cardiovascular (CV) outcomes by baseline renal function in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). RESEARCH DESIGN AND METHODS: Least squares mean ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · February 2020
BACKGROUND: Previous provider-directed electronic messaging interventions have not by themselves improved anticoagulation use in patients with atrial fibrillation. Direct engagement with providers using academic detailing coupled with electronic messaging ...
Full textLink to itemCite
Journal ArticleCirculation · January 7, 2020
BACKGROUND: The use of nonsteroidal anti-inflammatory drugs (NSAIDs) with oral anticoagulants has been associated with an increased risk of bleeding. We investigated the risk of bleeding and major cardiovascular outcomes in patients with atrial fibrillatio ...
Full textLink to itemCite
Journal ArticleEur J Intern Med · January 2020
BACKGROUND: Periodontitis has been associated with coronary artery disease, but the impact of a periodontal treatment on the endothelial function of patients with a recent ST-segment elevation myocardial infarction (STEMI) was not investigated. METHODS: Ra ...
Full textLink to itemCite
Journal ArticleClin Appl Thromb Hemost · 2020
This practical guidance, endorsed by the Brazilian Society of Thrombosis and Hemostasis and The Brazilian Society of Angiology and Vascular Surgery, the International Union of Angiology and the European Venous Forum, aims to provide physicians with clear g ...
Full textLink to itemCite
Journal ArticleRev Bras Ter Intensiva · 2020
INTRODUCTION: Pro-inflammatory markers play a significant role in the disease severity of patients with COVID-19. Thus, anti-inflammatory therapies are attractive agents for potentially combating the uncontrolled inflammatory cascade in these patients. We ...
Full textLink to itemCite
Journal ArticleRev Bras Ter Intensiva · 2020
OBJECTIVE: The infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and is considered a pandemic. The most common manifestation of SARS-CoV-2 infection (coronavirus disease 2019 - COVID-19) is viral pneumon ...
Full textLink to itemCite
Journal ArticleCirculation · December 3, 2019
BACKGROUND: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation who have acute coronary syndromes (ACS), treated medically or with percutaneous coronary intervention (PCI), and those undergoing elective P ...
Full textLink to itemCite
Journal ArticleInternational journal of cardiology · December 2019
AimsAt present, there is little evidence on how to treat subclinical atrial fibrillation (SCAF) or atrial high rate episodes (AHREs) detected by cardiac implantable electronic devices (CIEDs). Our aim was to assess current practice around oral ant ...
Full textCite
Journal ArticleJournal of thrombosis and haemostasis : JTH · December 2019
BackgroundExtended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess ...
Full textCite
Journal ArticleAm Heart J · December 2019
International differences in management/outcomes among patients with type 2 diabetes and heart failure (HF) are not well characterized. We sought to evaluate geographic variation in treatment and outcomes among these patients. METHODS AND RESULTS: Among 14 ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · December 2019
BACKGROUND: Medicare insurance claims may provide an efficient means to ascertain follow-up of older participants in clinical research. We sought to determine the accuracy and completeness of claims- versus site-based follow-up with clinical event committe ...
Full textLink to itemCite
Journal ArticleCirculation · November 12, 2019
BACKGROUND: Once-weekly exenatide (EQW) had a neutral effect on hospitalization for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with no differential treatment effect on major adverse cardiac events by baselin ...
Full textLink to itemCite
Journal ArticleCirculation · November 5, 2019
BACKGROUND: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therapies for secondary prevention in patients with low-density lipoprotein cholesterol ≥70 mg/dL or non-high-density lipoprotein cholesterol ≥100 mg/dL despite m ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 1, 2019
Whether patients with atrial fibrillation (AF) and thyroid disease are clinically distinct from those with AF and no thyroid disease is unknown. Furthermore, the effectiveness of anticoagulation for prevention of AF-related thromboembolic events in patient ...
Full textLink to itemCite
Journal ArticleCardiovasc Drugs Ther · October 2019
PURPOSE: To study whether polypharmacy or drug-drug interactions have differential effect on safety and efficacy in patients treated with direct oral anticoagulants (DOACs) versus warfarin. METHODS: We performed a systematic review and meta-analysis of stu ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 15, 2019
Fragmented care following elective surgery has been associated with poor outcomes. The association between fragmented care and outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) is unknown. We examined patients who underwent TAV ...
Full textLink to itemCite
Journal ArticleEur Heart J · September 1, 2019
AIMS: The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2019
UNLABELLED: Patients with a recent acute coronary syndrome (ACS) receiving oral antiplatelets and anticoagulants are at risk for bleeding and subsequent adverse non-bleeding-related events. METHODS: In this post hoc analysis, we evaluated 7,392 high-risk p ...
Full textLink to itemCite
Journal ArticleEur J Intern Med · September 2019
BACKGROUND: Worldwide atrial fibrillation (AF) prevalence varies between 0.1% and 4.0%, and has been increasing. Little is known about the prevalence of AF in Brazil. Our objective was to estimate the prevalence of AF in several regions of Brazil using rec ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · August 15, 2019
BACKGROUND: We investigated the use of different antithrombotic therapies at baseline among patients with a history of atrial fibrillation (AF), type 2 diabetes, and established atherosclerotic cardiovascular disease (ASCVD) enrolled in the Trial Evaluatin ...
Full textLink to itemCite
Journal ArticleJAMA Neurol · August 1, 2019
IMPORTANCE: Translating evidence into clinical practice in the management of acute ischemic stroke (AIS) and transient ischemic attack (TIA) is challenging, especially in low- and middle-income countries. OBJECTIVE: To assess the effect of a multifaceted q ...
Full textOpen AccessLink to itemCite
Journal ArticleJAMA Cardiol · August 1, 2019
IMPORTANCE: The antithrombotic treatment of patients with atrial fibrillation (AF) and coronary artery disease, in particular with acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI), poses a significant treatment dilemma in clini ...
Full textLink to itemCite
Journal ArticleLancet Diabetes Endocrinol · August 2019
BACKGROUND: After acute coronary syndrome, diabetes conveys an excess risk of ischaemic cardiovascular events. A reduction in mean LDL cholesterol to 1·4-1·8 mmol/L with ezetimibe or statins reduces cardiovascular events in patients with an acute coronary ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 9, 2019
Most patients with atrial fibrillation (AF) and risk factors for stroke require oral anticoagulation (OAC) to decrease the risk of stroke or systemic embolism. This is now best achieved with direct oral anticoagulants that decrease the risk of intracranial ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · July 2019
We explored associations between INR measures and clinical outcomes in patients with AF using warfarin, and whether INR history predicted future INR measurements. We included patients in ARISTOTLE who were randomized to and received warfarin. Among patient ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2019
BACKGROUND: Heart failure (HF) following acute coronary syndromes (ACS) is associated with worse prognosis; however, the efficacy and safety of ticagrelor in patients with HF and if ticagrelor influences the risk of new-onset HF are unknown. METHODS: We ex ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · July 2019
BACKGROUND: In the CHAMPION PHOENIX trial, cangrelor reduced the primary composite end point of death, myocardial infarction (MI), ischemia-driven revascularization, or stent thrombosis at 48 hours. This study aimed to explore the impact of event adjudicat ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 11, 2019
BACKGROUND: The efficacy of ticagrelor in the long-term post-ST-segment elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remains uncertain. OBJECTIVES: The purpose of this study was to evaluate the efficacy of ticagrelor when compa ...
Full textLink to itemCite
Journal ArticleEur Heart J · May 14, 2019
AIMS: Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta-analysis, we aimed to assess outcomes with reduced-dose NOACs when given as ...
Full textLink to itemCite
Journal ArticleCirculation · May 14, 2019
BACKGROUND: Guidelines caution against the use of non-vitamin K antagonist oral anticoagulants in patients with extremely high (>120 kg) or low (≤60 kg) body weight because of a lack of data in these populations. METHODS: In a post hoc analysis of ARISTOTL ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · May 13, 2019
The Academic Research Consortium (ARC) and the Standardized Data Collection for Cardiovascular Trials Initiative have recently published updated clinical and angiographic endpoint definitions for percutaneous coronary intervention trials. The aim of this d ...
Full textLink to itemCite
Journal ArticleClin Cardiol · May 2019
BACKGROUND: The optimal anticoagulation strategy for patients with atrial fibrillation (AF) and bioprosthetic valve (BPV) replacement or native valve repair remains uncertain. HYPOTHESIS: We evaluated the safety and efficacy of apixaban vs warfarin in pati ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2019
BACKGROUND: Peripheral blood metabolite profiles have yielded mechanistic insights into various cardiovascular disease states. We hypothesized that peripheral blood metabolite profiles would be associated with new onset atrial fibrillation (AF). METHODS AN ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · May 1, 2019
IMPORTANCE: Studies have found that patients at high cardiovascular risk often fail to receive evidence-based therapies in community practice. OBJECTIVE: To evaluate whether a multifaceted quality improvement intervention can improve the prescription of ev ...
Full textLink to itemCite
Journal ArticleN Engl J Med · April 18, 2019
BACKGROUND: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. METHODS: In an international trial with a two-by-two factorial ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · April 2019
Warfarin is dependent on multiple hepatic enzymes for metabolism while apixaban is a substrate for P-glycoprotein (P-gp) transport and hepatic CYP3A4 metabolism. The aim of this analysis was to assess the impact of interacting medication use on the treatme ...
Full textLink to itemCite
Journal ArticleJAMA · March 19, 2019
IMPORTANCE: Clinical decisions are ideally based on evidence generated from multiple randomized controlled trials (RCTs) evaluating clinical outcomes, but historically, few clinical guideline recommendations have been based entirely on this type of evidenc ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · March 1, 2019
IMPORTANCE: It is unknown whether coronary revascularization, when added to optimal medical therapy, improves prognosis in patients with stable ischemic heart disease (SIHD) at increased risk of cardiovascular events owing to moderate or severe ischemia. O ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · February 15, 2019
Although in situ internal mammary artery (is-IMA) grafting remains the most frequent conduit in coronary artery bypass grafting (CABG), circumstances may necessitate free grafting of the IMA (f-IMA), though differences in outcomes have not been fully chara ...
Full textLink to itemCite
Journal ArticleCirculation · February 12, 2019
BACKGROUND: Modern cardiometabolic clinical trials often include cardiovascular death as a component of a composite primary outcome, requiring central adjudication by a clinical events committee to classify cause of death. However, sometimes the cause of d ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · February 5, 2019
BACKGROUND: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute co ...
Full textLink to itemCite
Journal ArticleCirculation · February 5, 2019
BACKGROUND: Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding, may occur. Ther ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · February 5, 2019
Background Using data from the GARFIELD - AF (Global Anticoagulant Registry in the FIELD -Atrial Fibrillation), we evaluated the impact of chronic kidney disease ( CKD ) stage on clinical outcomes in patients with newly diagnosed atrial fibrillation ( AF ) ...
Full textLink to itemCite
Journal ArticleHeart · February 2019
OBJECTIVES: Compare the effect of apixaban and warfarin on coagulation and primary haemostasis biomarkers in atrial fibrillation (AF). METHODS: The biomarker substudy from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibri ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · February 2019
BACKGROUND: Clinical Endpoint Classification (CEC) in clinical trials allows FOR standardized, systematic, blinded, and unbiased adjudication of investigator-reported events. We quantified the agreement rates in the STABILITY trial on 15,828 patients with ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · February 2019
BACKGROUND: Patients with atrial fibrillation (AF) often have multi-morbidity, defined as ≥3 comorbid conditions. Multi-morbidity is associated with polypharmacy, adverse events, and frailty potentially altering response to anticoagulation. We sought to de ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · January 1, 2019
To examine patterns of preadmission and discharge antithrombotic therapies in coronary artery disease (CAD) and atrial fibrillation (AF) patients admitted for acute myocardial infarction (AMI), we performed a retrospective analysis of the Acute Coronary Tr ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2019
BACKGROUND: Translating evidence into clinical practice in the management of acute ischemic stroke (AIS) and transient ischemic attack (TIA) is challenging especially in low- and middle-income countries. OBJECTIVES: The aim of this study is to assess the e ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2019
BACKGROUND: Translating evidence into clinical practice in the management of high cardiovascular risk patients is challenging. Few quality improvement interventions have rigorously evaluated their impact on both patient care and clinical outcomes. OBJECTIV ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · January 1, 2019
In 2015, 3 independent meta-analyses raised concerns about digoxin therapy being associated with an increased mortality risk in patients with atrial fibrillation (AF) and with heart failure (HF). Although several other studies have been published since the ...
Full textLink to itemCite
Journal ArticleClin Appl Thromb Hemost · 2019
A variety of viral infections are associated with hypercoagulable states and may be linked to the development of deep venous thrombosis and pulmonary embolism. The Zika and Chikungunya viral infections spread through the South and Central American continen ...
Full textLink to itemCite
Journal ArticleClin Appl Thromb Hemost · 2019
Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and u ...
Full textLink to itemCite
Journal ArticleClinics (Sao Paulo) · 2019
OBJECTIVE: To develop and validate a questionnaire to assess the knowledge of mechanical ventilation among final-year medical students in Brazil. METHODS: A cross-sectional study conducted between October 2015 and October 2017 involving 554 medical student ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · December 25, 2018
BACKGROUND: Diabetes confers an increased risk for atherosclerotic cardiovascular disease, but less is known about the independent risk diabetes confers on major cardiovascular and limb events in patients with symptomatic peripheral artery disease (PAD) on ...
Full textOpen AccessLink to itemCite
Journal ArticleVasc Med · December 2018
Patients with peripheral artery disease (PAD) are at heightened risk of cardiovascular morbidity and mortality. We sought to evaluate the risk of concomitant coronary artery disease (CAD) in patients with symptomatic PAD versus PAD without diagnosed CAD, a ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · December 2018
Background Cardiovascular clinical trials have traditionally incorporated separate time-to-first-event analyses for their primary efficacy and safety comparisons, but this framework has a number of limitations, including limited patient-centeredness and a ...
Full textLink to itemCite
Journal ArticleN Engl J Med · November 29, 2018
BACKGROUND: Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), wou ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · November 1, 2018
BACKGROUND: Controversies exist over the appropriate definition for peri-procedural myocardial infarction (PPMI) and its association with mortality. This study aims to evaluate one-year survival following percutaneous coronary intervention (PCI) and the as ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · November 1, 2018
IMPORTANCE: Loading doses of atorvastatin did not show reduction on clinical outcomes in the overall population of patients with acute coronary syndrome (ACS) enrolled in the Statins Evaluation in Coronary Procedures and Revascularization (SECURE-PCI) tria ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2018
A systematic, nationwide assessment of care of patients with hypertension in Brazil is needed. The objective of the First National Registry of Patients with Hypertension in Brazil is to evaluate the clinical profile, treatment patterns, and outcomes of dia ...
Full textLink to itemCite
Journal ArticleLancet · October 27, 2018
BACKGROUND: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine t ...
Full textLink to itemCite
Journal ArticleCirculation · October 16, 2018
BACKGROUND: Atrial fibrillation is associated with an increased risk of death. High-sensitivity troponin T, growth differentiation factor-15, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and interleukin-6 levels are predictive of cardiovascular e ...
Full textLink to itemCite
Journal ArticleCirculation · October 2, 2018
BACKGROUND: Direct oral anticoagulants (DOACs) are surpassing warfarin as the anticoagulant of choice for stroke prevention in nonvalvular atrial fibrillation. DOAC outcomes in elective periprocedural settings have not been well elucidated and remain a sou ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · October 2, 2018
Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once-weekly resulted in a nonsignificant reduction in major adverse cardiovascular events ( MACEs ) and a nominal 14% reduction in all-cause mortality in 14 752 patients ...
Full textOpen AccessLink to itemCite
Journal ArticleCardiovasc Drugs Ther · October 2018
BACKGROUND: The role of beta-blockers in patients with acute coronary syndromes is mainly derived from studies including patients with ST-segment elevation myocardial infarction. Little is known about the use of beta-blockers and associated long-term clini ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · October 2018
BACKGROUND: Stroke prophylaxis in patients with atrial fibrillation (AF) and heart failure (HF) in the era of direct oral anticoagulants is not well characterized. Using data from American Heart Association Get With The Guidelines-AFIB, we sought to evalua ...
Full textLink to itemCite
Journal ArticleN Engl J Med · September 20, 2018
BACKGROUND: Patients who are hospitalized for medical illness remain at risk for venous thromboembolism after discharge, but the role of extended thromboprophylaxis in the treatment of such patients is a subject of controversy. METHODS: In this randomized, ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · September 15, 2018
BACKGROUND: The National Cardiovascular Data Registry (NCDR®) Database is commonly used for quality-improvement initiatives in North America, but little is known about the application of this tool in other regions of the world. METHODS: All consecutive pat ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · September 10, 2018
OBJECTIVES: The aim of this study was to evaluate incidence, care patterns, and clinical outcomes in patients developing new-onset atrial fibrillation (AF) following transcatheter aortic valve replacement (TAVR). BACKGROUND: Pre-procedural AF has been asso ...
Full textLink to itemCite
Journal ArticleAm J Med · September 2018
BACKGROUND: Direct oral anticoagulants (DOAC) are at least non-inferior to warfarin in efficacy and safety among patients with nonvalvular atrial fibrillation. Limited evidence is available regarding outcomes for nonvalvular atrial fibrillation patients wi ...
Full textLink to itemCite
Journal ArticleEur Heart J · August 21, 2018
Real-world data (RWD) has been defined as data generated outside of traditional randomized clinical trials (RCTs). Though RWD has received increasing attention from regulatory authorities and professional societies, dividing evidence into that derived from ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 14, 2018
BACKGROUND: There is little mechanistic information on factors predisposing atrial fibrillation (AF) patients to thromboembolism or bleeding, but generation of nitric oxide (NO) might theoretically contribute to both. OBJECTIVES: The authors tested the hyp ...
Full textLink to itemCite
Journal ArticleHeart · August 2018
OBJECTIVE: To assess stroke/systemic embolism, major bleeding and other outcomes, and treatment effect of apixaban versus warfarin, in patients with atrial fibrillation (AF) and different types of valvular heart disease (VHD), using data from the Apixaban ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2018
BACKGROUND: The safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remain uncertain. OBJECTIVES: The primary objective of the TicagRElor in pAtients with ST elevation myocardial i ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2018
BACKGROUND: There is substantial variability among hospitals in critical care unit (CCU) utilization for patients admitted with non-ST-Segment Elevation Acute Coronary Syndromes (NSTE ACS). We estimated the potential cost saving if all hospitals adopted lo ...
Full textLink to itemCite
Journal ArticleNat Rev Cardiol · August 2018
In patients with manifestations of cardiovascular disease, acetylsalicylic acid (popularly known as aspirin) has been the mainstay of treatment for decades owing to its capacity to reduce the risk of ischaemic events. Accordingly, novel antithrombotic ther ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · July 6, 2018
BACKGROUND: Few data exist on regional systems of care for the treatment of ST-segment-elevation myocardial infarction (STEMI) in developing countries. Our objective was to describe temporal trends in 30-day mortality and identify predictors of mortality a ...
Full textLink to itemCite
Journal ArticleInt J Qual Health Care · July 1, 2018
OBJECTIVE: (i) To describe how aligned the 'Choosing Wisely' concept is with the medical culture among Brazilian cardiologists and (ii) to identify predictors for physicians' preference for avoiding wasteful care. DESIGN: Cross-sectional study. SETTING: Br ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2018
BACKGROUND: Patients with peripheral artery disease (PAD) are known to have an increased risk of ischemic cardiovascular events. However, the influence of concomitant PAD on first and subsequent recurrent ischemic events after an acute coronary syndrome (A ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · July 1, 2018
Contrast is a recommended but frequently unused tool in transthoracic echocardiography to improve detection of left ventricular thrombus in patients with ejection fraction (EF) ≤35%. The clinical and economic outcomes of a possible solution (i.e., universa ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2018
BACKGROUND: Length of stay after non-ST-segment elevation myocardial infarction (NSTEMI) continues to decrease, but information to guide duration of hospitalization is limited. METHODS: We used landmark analyses, in which the landmark defined potential day ...
Full textLink to itemCite
ConferenceDiabetes · July 1, 2018
Background: EXSCEL was a multinational, randomized, blinded, placebo-controlled, pragmatic CV outcome trial of once-weekly exenatide on the background of usual care. We report exenatide’s impact on estimated glomerular filtration rate (eGFR), new m ...
Full textCite
Journal ArticleAm Heart J · June 2018
BACKGROUND: The optimal antithrombotic strategy for patients with atrial fibrillation (AF) who develop acute coronary syndrome (ACS) and/or the need for percutaneous coronary intervention (PCI) is uncertain. The risk of bleeding is a major concern when ora ...
Full textLink to itemCite
Journal ArticleMedicine · June 2018
IntroductionThe prevalence of metabolic syndrome (MetS) and MetS-related stroke is set to increase dramatically in coming decades. MetS is a complex disease that includes endothelial dysfunction, insulin resistance, diabetes, hypertension, ectopic ...
Full textCite
Journal ArticleJACC Cardiovasc Interv · May 14, 2018
Patients in coronary intervention trials may require more than 1 procedure to complete the intended revascularization strategy. However, these staged interventions are not consistently defined. Standardized definitions are needed to allow meaningful compar ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · May 1, 2018
IMPORTANCE: The bleeding safety of ticagrelor in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy remains uncertain. OBJECTIVE: To evaluate the short-term safety of ticagrelor when compared with clopidogrel in patients wit ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · May 2018
To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Tenth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, on September 22 and 23, 2017. This scientific program ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2018
OBJECTIVES: Perioperative myocardial infarction (MI) after coronary artery bypass graft surgery (CABG) has been associated with adverse outcome. Whether perioperative MI should be treated with dual antiplatelet therapy (DAPT) is unknown. We compared the ef ...
Full textLink to itemCite
Journal ArticleJAMA · April 3, 2018
IMPORTANCE: The effects of loading doses of statins on clinical outcomes in patients with acute coronary syndrome (ACS) and planned invasive management remain uncertain. OBJECTIVE: To determine if periprocedural loading doses of atorvastatin decrease 30-da ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · April 1, 2018
AIMS: We investigated baseline characteristics, antithrombotic use, and clinical outcomes of patients with atrial fibrillation (AF) and a thrombo-embolic event in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation ( ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2018
BACKGROUND: Previous evidence suggests that acute treatment with statins reduce atherosclerotic complications, including periprocedural myocardial infarction, but currently, there are no large, adequately powered studies to define the effects of early, hig ...
Full textLink to itemCite
Journal ArticleMedicine (Baltimore) · April 2018
INTRODUCTION: The metabolic syndrome is composed of several cardiovascular risk factors and has a high prevalence throughout the world. However, there are no systematic analyses or well-conducted meta-analyses to evaluate the relationship between metabolic ...
Full textLink to itemCite
Journal ArticleMedicine · April 2018
BackgroundThe prevalence of metabolic syndrome (MetS) and MetS-related stroke is set to increase dramatically in coming decades. MetS is a complex disease that includes endothelial dysfunction, insulin resistance, diabetes, hypertension, ectopic o ...
Full textCite
Journal ArticleMedicine · April 2018
BackgroundPatients with HIV have been found to suffer from lipid abnormalities, including elevated levels of total and LDL-cholesterol as well as triglyceride levels. Abnormal lipid levels are associated with an increased risk of developing cardio ...
Full textCite
Journal ArticleMedicine · April 2018
BackgroundAtherosclerosis is now widely recognized as a multifactorial disease with outcomes that arise from complex factors such as plaque components, blood flow, and inflammation. Epicardial adipose tissue (EAT) is a metabolically active fat dep ...
Full textCite
Journal ArticleJ Am Coll Cardiol · March 13, 2018
BACKGROUND: Digoxin is widely used in patients with atrial fibrillation (AF). OBJECTIVES: The goal of this paper was to explore whether digoxin use was independently associated with increased mortality in patients with AF and if the association was modifie ...
Full textLink to itemCite
Journal ArticleCureus · March 13, 2018
Coronary artery fistula (CAF) is a rare congenital anomaly, which is most commonly asymptomatic. In symptomatic cases, aneurysms can occur with complications of thromboembolic events. This report describes a rare case of CAF presenting with complications o ...
Full textLink to itemCite
Journal ArticleCureus · March 10, 2018
This report describes a case of aortic valve endocarditis with systemic and paradoxical pulmonary embolism in a patient with congenital interventricular communication. The patient underwent cardiac surgery and did not have a favorable outcome, presenting r ...
Full textLink to itemCite
ConferenceEur Heart J Acute Cardiovasc Care · March 2018
AIMS: The purpose of this study was to test whether different results between Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON (CHAMPION) PCI/PLATFORM and PHOENIX trials are due in part to different definitions of perc ...
Full textLink to itemCite
Journal ArticleAm J Med · March 2018
PURPOSE: We assessed outcomes among anticoagulated patients with atrial fibrillation and a history of falling, and whether the benefits of apixaban vs warfarin are consistent in this population. METHODS: Of the 18,201 patients in the Apixaban for Reduction ...
Full textLink to itemCite
Journal ArticleJ Stroke Cerebrovasc Dis · March 2018
BACKGROUND: It has been hypothesized that ischemic stroke can cause atrial fibrillation. By elucidating the mechanisms of neurogenically mediated paroxysmal atrial fibrillation, novel therapeutic strategies could be developed to prevent atrial fibrillation ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2018
BACKGROUND AND PURPOSE: Patients with prior stroke are at greater risk for recurrent cardiovascular events post-acute coronary syndromes (ACS) and may have a different risk/benefit profile with antithrombotic therapy than patients without prior stroke. MET ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2018
BACKGROUND: We assessed antiplatelet therapy use and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ARISTOTLE trial. METHODS: Patients were categorized based on the occurrence of PCI during follow-up (median 1.8 years); ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · March 1, 2018
IMPORTANCE: Patients with acute coronary syndrome (ACS) remain at high risk for experiencing recurrent ischemic events. Direct oral anticoagulants (DOAC) have been proposed for secondary prevention after ACS. OBJECTIVE: To evaluate the safety and efficacy ...
Full textLink to itemCite
Journal ArticleEur Heart J · February 7, 2018
AIMS: In atrial fibrillation (AF), mortality remains high despite effective anticoagulation. A model predicting the risk of death in these patients is currently not available. We developed and validated a risk score for death in anticoagulated patients wit ...
Full textLink to itemCite
Journal ArticleEuroIntervention · February 2, 2018
AIMS: The aim of this study was to determine the prognostic significance of periprocedural bleeding based on various definitions on 30-day and one-year all-cause mortality in patients undergoing routine or urgent percutaneous coronary intervention (PCI). M ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2018
BACKGROUND: Type 2 myocardial infarction (MI) is characterized by an imbalance between myocardial blood supply and demand, leading to myocardial ischemia without coronary plaque rupture, but its diagnosis is challenging. METHODS: In the TRACER trial, patie ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · February 1, 2018
BACKGROUND: Dyslipidemia is a major risk factor for cardiovascular events. The prognostic importance of lipoproteins in patients with atrial fibrillation is not well understood. We aimed to explore the association between apolipoprotein A1 (ApoA1) and B (A ...
Full textLink to itemCite
Journal ArticleIndian Heart J · 2018
BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outc ...
Full textLink to itemCite
Journal ArticleOpen Heart · 2018
OBJECTIVE: We investigated the association between obesity and biomarkers indicating cardiac or renal dysfunction or inflammation and their interaction with obesity and outcomes. METHODS: A total of 14 753 patients in the Apixaban for Reduction In STroke a ...
Full textLink to itemCite
Chapter · January 1, 2018
The burden of atrial fibrillation will grow as our population ages and the presence of comorbidities, such as hypertension and obesity, increases. The detection of subclinical atrial fibrillation remains an active area of research, and defining the optimal ...
Full textCite
ConferenceAm J Med · December 2017
BACKGROUND: Cancer is associated with a prothrombotic state and increases the risk of thrombotic events in patients with atrial fibrillation. We described the clinical characteristics and outcomes and assessed the safety and efficacy of apixaban versus war ...
Full textLink to itemCite
Journal ArticleJ Crit Care · December 2017
PURPOSE: Critically ill patients with hyperglycemia have worse prognosis. The degree to which glycemic control is achieved following CABG surgery and the association with clinical outcomes is not well understood. MATERIALS AND METHODS: We studied patients ...
Full textLink to itemCite
Journal ArticleDiabetes Care · December 2017
OBJECTIVE: We evaluated the specific causes of death and their associated risk factors in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD). RESEARCH DESIGN AND METHODS: We used data from the Trial Ev ...
Full textLink to itemCite
Journal ArticleStroke · December 2017
BACKGROUND AND PURPOSE: Few data exist on the long-term outcomes of patients with spontaneous echo contrast (SEC), left atrial/left atrial appendage (LA/LAA) thrombus, and complex aortic plaque (CAP), in patients with atrial fibrillation receiving oral ant ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · November 2017
To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Ninth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, on October 15, 2016. This scientific program was devel ...
Full textLink to itemCite
Journal ArticleLancet · October 21, 2017
BACKGROUND: Inflammation in the tumour microenvironment mediated by interleukin 1β is hypothesised to have a major role in cancer invasiveness, progression, and metastases. We did an additional analysis in the Canakinumab Anti-inflammatory Thrombosis Outco ...
Full textLink to itemCite
Journal ArticleLancet · October 14, 2017
BACKGROUND: Oral anticoagulation is underused in patients with atrial fibrillation. We assessed the impact of a multifaceted educational intervention, versus usual care, on oral anticoagulant use in patients with atrial fibrillation. METHODS: This study wa ...
Full textLink to itemCite
Journal ArticleAm J Med · October 2017
BACKGROUND: Most diabetes and cardiovascular studies have been conducted in white patients, with data being extrapolated to other population groups. METHODS: For this analysis, patient-level data were extracted from 5 randomized clinical trials in patients ...
Full textLink to itemCite
Journal ArticleClin Cardiol · October 2017
BACKGROUND: In 2011, the US Food and Drug Administration requested that GlaxoSmithKline perform retrospective adjudication of cardiovascular (CV) events reported in the bupropion drug-development trials for smoking cessation. HYPOTHESIS: Retrospective adju ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2017
UNLABELLED: Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide. However, there are few contemporary comparative data on AF from middle-income countries. METHODS: Baseline characteristics of the IMPACT-AF trial were analyzed to asses ...
Full textLink to itemCite
Journal ArticleN Engl J Med · September 21, 2017
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · September 14, 2017
BACKGROUND: Greater understanding of differences between men and women with coronary heart disease is needed. METHODS AND RESULTS: In this post hoc analysis of the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) tria ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 23, 2017
BACKGROUND: Prior studies have demonstrated a link between the metabolic syndrome and increased risk of cardiovascular mortality. Whether the metabolic syndrome is associated with sudden cardiac death is uncertain. METHODS AND RESULTS: We characterized the ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 21, 2017
BACKGROUND: Patients receiving oral anticoagulation in addition to dual-antiplatelet therapy are known to be at high risk for bleeding events; thus, the selection of a drug-eluting stent (DES) versus a bare metal stent (BMS) can have important implications ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · July 11, 2017
BACKGROUND: Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and s ...
Full textLink to itemCite
Journal ArticleAnn Thorac Surg · July 2017
BACKGROUND: Perioperative use of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEis) in patients undergoing cardiac operations remains controversial. The current practice of discontinuing renin-angiotensin-system inhib ...
Full textLink to itemCite
Journal ArticleJ Thromb Haemost · July 2017
Essentials The association of body weight and patient-important outcomes remains unknown. Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were searched. Risk of outcomes varying among body weight subgroups is not attributable t ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2017
BACKGROUND: Device-detected subclinical atrial fibrillation (AF) refers to infrequent, short-lasting, asymptomatic AF that is detected only with long-term continuous monitoring. Subclinical AF is common and associated with an increased risk of stroke; howe ...
Full textLink to itemCite
Journal ArticleRes Pract Thromb Haemost · July 2017
BACKGROUND: Platelet transfusions are commonly used to treat critically ill patients with thrombocytopenia. Whether platelet transfusions are associated with a reduction in the risk of major bleeding is unknown. PATIENTS/METHODS: Observational cohort study ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 23, 2017
BACKGROUND: Cardiac biomarkers are independent risk markers in atrial fibrillation, and the novel biomarker-based ABC stroke score (age, biomarkers, and clinical history of prior stroke) was recently shown to improve the prediction of stroke risk in patien ...
Full textLink to itemCite
Journal ArticleSyst Rev · June 19, 2017
BACKGROUND: Preliminary evidence suggests statins may reduce major perioperative vascular events. However, evidence is limited to observational studies, underpowered trials, and non-comprehensive systematic reviews. This review aims to assess the effects o ...
Full textLink to itemCite
Journal ArticleBlood · June 1, 2017
We investigated the frequency and characteristics of intracranial hemorrhage (ICH), the factors associated with the risk of ICH, and outcomes post-ICH overall and by randomized treatment. We identified patients with ICH from the overall trial population en ...
Full textLink to itemCite
Journal ArticleCardiovasc Drugs Ther · June 2017
PURPOSE: Vitamin K antagonists (VKAs) are the standard of care for stroke prevention in patients with atrial fibrillation (AF); therefore, there is not equipoise when comparing newer oral anticoagulants with placebo in this setting. METHODS: To explore the ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · May 2017
Myonecrosis after coronary artery bypass graft (CABG) surgery is associated with excess mortality. Tranexamic acid (TA), an anti-fibrinolytic agent, has been shown to reduce peri-operative blood loss without increasing the risk of myocardial infarction (MI ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · May 2017
OBJECTIVE: Acute coronary syndrome (ACS) trials typically use a composite primary outcome (myocardial infarction [MI], stroke, or cardiovascular death), but differential patient characteristics, timing, and consequences associated with individual component ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · May 1, 2017
IMPORTANCE: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin therapy in preventing stroke and all-cause death while causing significantly f ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · April 24, 2017
BACKGROUND: End points and adverse events (AEs) are collected separately in clinical trials, yet regulatory requirements for serious AE reporting vary across regions, so classifying end points according to seriousness criteria can be useful in global trial ...
Full textLink to itemCite
Journal ArticleHeart · April 2017
OBJECTIVE: We describe the incidence, location and management of non-major bleeding, and assess the association between non-major bleeding and clinical outcomes in patients with atrial fibrillation (AF) receiving anticoagulation therapy enrolled in Apixaba ...
Full textLink to itemCite
Journal ArticleAm J Med · April 2017
BACKGROUND: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used in perioperative pain management of patients undergoing coronary artery bypass graft surgery. However, the association of periprocedural use of NSAIDs and clinical outcomes after c ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2017
BACKGROUND: Patients with impaired glucose tolerance have an elevated risk of cardiovascular (CV) death; however, the causes and risk factors associated with non-CV deaths are poorly understood. METHODS: The NAVIGATOR trial enrolled 9,306 participants with ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2017
UNLABELLED: Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit. We sought to compare the relative effects of ischemic and bleeding events on mortality. METHODS: In ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · March 1, 2017
IMPORTANCE: Subclinical atrial fibrillation (AF) is associated with an increased risk for stroke. OBSERVATIONS: Subclinical AF is asymptomatic, short in duration, and usually detected with long-term, continuous monitoring. Most prior studies have explored ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2017
BACKGROUND: Patients with atrial fibrillation (AF) are prone to cardiovascular events and anticoagulation-related bleeding complications. We hypothesized that patients with anemia are at increased risk for these outcomes. METHODS: We performed a post hoc a ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2017
UNLABELLED: Preliminary evidence suggests that statins may prevent major perioperative vascular complications. METHODS: We randomized 648 statin-naïve patients who were scheduled for noncardiac surgery and were at risk for a major vascular complication. Pa ...
Full textLink to itemCite
Journal ArticleClinics (Sao Paulo) · February 1, 2017
OBJECTIVE:: To present self-assessments of knowledge about mechanical ventilation made by final-year medical students, residents, and physicians taking qualifying courses at the Brazilian Society of Internal Medicine who work in urgent and emergency settin ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · January 17, 2017
BACKGROUND: We studied (1) the rates of stroke or systemic embolism and bleeding in patients with atrial fibrillation and peripheral artery disease (PAD) and (2) the efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation with ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · January 15, 2017
BACKGROUND: Evidence supporting use of antithrombotic therapy in atrial fibrillation (AF) is based mainly on data from patients with permanent, persistent, or paroxysmal AF. Less is known about the risk following a new diagnosis of AF and the efficacy and ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · January 13, 2017
BACKGROUND: Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new-onset diabetes mellitus, cardiovas ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 14, 2016
BACKGROUND: Stroke is among the leading causes of disability and death in the United States, and nearly 7 million adults are currently alive after experiencing a stroke. Although the risks associated with having a stroke are well established, we know surpr ...
Full textLink to itemCite
ConferenceBlood · December 2, 2016
AbstractDirect oral anticoagulants (DOACs) and low molecular weight heparin transitioned to warfarin are widely used for stroke prevention in AF (AF) and in acute venous thromboembo ...
Full textCite
Journal ArticleAnn Intensive Care · December 2016
BACKGROUND: Previous studies have suggested that prediction models for mortality should be adjusted for additional risk factors beyond the Acute Physiology and Chronic Health Evaluation (APACHE) score. Our objective was to identify risk factors independent ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · December 1, 2016
BACKGROUND: The effect of socioeconomic stressors on the incidence of cardiovascular disease (CVD) is currently open to debate. Using time-series analysis, our study aimed to evaluate the relationship between unemployment rate and hospital admission for ac ...
Full textOpen AccessLink to itemCite
Journal ArticleDiabetes Care · December 2016
OBJECTIVE: To evaluate chronic kidney disease (CKD) and cardiovascular outcomes in TECOS (Clinical trial reg. no. NCT00790205, clinicaltrials.gov) participants with type 2 diabetes and cardiovascular disease treated with sitagliptin, a dipeptidyl peptidase ...
Full textLink to itemCite
Journal ArticleCirculation · November 29, 2016
BACKGROUND: Atrial fibrillation is associated with increased but variable risk of stroke. Our aim was to validate the recently developed biomarker-based ABC (age, biomarkers [high-sensitivity troponin and N-terminal fragment B-type natriuretic peptide], an ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2016
BACKGROUND: Contemporary studies assessing the frequency, characteristics, and outcomes of serious infections (SIs) in patients presenting a ST-elevation myocardial infarction are scarce. METHODS: Prospective cohort of consecutive patients undergoing prima ...
Full textLink to itemCite
Journal ArticleEur Heart J · October 7, 2016
AIMS: The prognostic implication of adiposity on clinical outcomes in atrial fibrillation (AF) patients treated with oral anticoagulation is unclear. METHODS AND RESULTS: A total of 17 913 patients in the Apixaban for Reduction in Stroke and Other Thromboe ...
Full textLink to itemCite
Journal ArticleHematol Oncol Clin North Am · October 2016
Direct oral anticoagulants (DOACs) have been approved for the treatment of venous thromboembolism and atrial fibrillation based on randomized controlled trials (RCTs) of direct comparisons with vitamin K antagonists. Despite having more than 100,000 patien ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · September 13, 2016
BACKGROUND: The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low-density lipoprotein-cholesterol (LDL-C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · September 1, 2016
IMPORTANCE: In the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the standard dose of apixaban was 5 mg twice daily; patients with at least 2 dose-reduction criteria-80 years or older, wei ...
Full textLink to itemCite
Journal ArticleClin Cardiol · September 2016
Associations between atrial fibrillation (AF), outcomes, and response to antiplatelet therapies in patients with acute coronary syndrome (ACS) managed medically without revascularization remain uncertain. We examined these associations for medically manage ...
Full textLink to itemCite
Journal ArticleN Engl J Med · August 11, 2016
BACKGROUND: Patients with acute medical illnesses are at prolonged risk for venous thrombosis. However, the appropriate duration of thromboprophylaxis remains unknown. METHODS: Patients who were hospitalized for acute medical illnesses were randomly assign ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2016
BACKGROUND: Antithrombotic therapy plays an important role in the treatment of non-ST-segment elevation acute coronary syndromes (NSTE ACS) but is associated with bleeding risk. Advanced age may modify the relationship between efficacy and safety. METHODS: ...
Full textLink to itemCite
Journal ArticleBr J Haematol · August 2016
Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires monitoring of the international normalized ratio (INR). We evaluated the agreement between two INR audit parameters, frequency in range (FIR) and proportion of ti ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · August 2016
BACKGROUND: A registry assessing the care of hypertensive patients in daily clinical practice in public and private centers in various Brazilian regions has not been conducted to date. Such analysis is important to elucidate the effectiveness of this care. ...
Full textLink to itemCite
Journal ArticleRespir Res · July 11, 2016
BACKGROUND: Despite the high mortality in patients with pneumonia admitted to an ICU, data on risk factors for death remain limited. METHODS: In this secondary analysis of PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial), we focused on the ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2016
BACKGROUND: Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding. We evaluated whether the use of glycoprotein IIb/IIIa inhibitor (GPI) impacts the relative efficacy and safety of ticagrelor ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · July 1, 2016
IMPORTANCE: Renal impairment confers an increased risk of stroke, bleeding, and death in patients with atrial fibrillation. Little is known about the efficacy and safety of apixaban in relation to renal function changes over time. OBJECTIVES: To evaluate c ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 27, 2016
BACKGROUND: Most studies of risk assessment or stratification in patients with myocardial infarction (MI) have been static and fail to account for the evolving nature of clinical events and care processes. We sought to identify predictors of mortality, car ...
Full textOpen AccessLink to itemCite
Journal ArticleBMJ · June 15, 2016
OBJECTIVE: To determine whether the treatment effect of apixaban versus warfarin differs with increasing numbers of concomitant drugs used by patients with atrial fibrillation. DESIGN: Post hoc analysis performed in 2015 of results from ARISTOTLE (apixab ...
Full textLink to itemCite
Journal ArticleLancet · June 4, 2016
BACKGROUND: The benefit of oral anticoagulation in atrial fibrillation is based on a balance between reduction in ischaemic stroke and increase in major bleeding. We aimed to develop and validate a new biomarker-based risk score to improve the prognosticat ...
Full textLink to itemCite
Journal ArticleAm J Med · June 2016
BACKGROUND: The role of triple antithrombotic therapy vs dual antithrombotic therapy in patients with both atrial fibrillation and coronary artery disease remains unclear. This study explores the differences in treatment practices and outcomes between trip ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2016
BACKGROUND: Atrial fibrillation (AF) is an important and growing public health problem worldwide, but data about its actual prevalence, therapeutic management, and clinical outcomes in middle- to low-income countries are scarce. DESIGN: The First Brazilian ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2016
Atrial fibrillation (AF) is common, increasing as the population ages, and a major cause of embolic stroke. While oral anticoagulation (OAC) is highly effective at preventing stroke in patients with AF, it continues to be underused in eligible patients wor ...
Full textLink to itemCite
Journal ArticleStroke · June 2016
BACKGROUND AND PURPOSE: Epidemiological data about stroke are scarce in low- and middle-income Latin-American countries. We investigated annual incidence of first-ever stroke and transient ischemic attack (TIA) and 30-day case-fatality rates in a populatio ...
Full textLink to itemCite
Journal ArticleEur Heart J · May 21, 2016
AIMS: Atrial fibrillation (AF) is associated with an increased risk of stroke, which is currently estimated by clinical characteristics. The cardiac biomarkers N-terminal fragment B-type natriuretic peptide (NT-proBNP) and cardiac troponin high-sensitivity ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · May 2016
AIMS: History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation (AF). We analyzed outcomes in relation to history of bleeding and randomization in ARISTOTLE trial patients. METHODS AND RESULTS: The on-treatment safety pop ...
Full textLink to itemCite
Journal ArticleAm J Med · May 2016
The North American Thrombosis Forum Atrial Fibrillation Action Initiative consensus document is a comprehensive yet practical briefing document focusing on stroke and bleeding risk assessment in patients with atrial fibrillation, as well as recommendations ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · May 1, 2016
IMPORTANCE: Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to ...
Full textLink to itemCite
Journal ArticleCirculation · April 19, 2016
BACKGROUND: Representation by age ensures appropriate translation of clinical trial results to practice, but, historically, older patients have been underrepresented in clinical trial populations. As the general population has aged, it is unknown whether c ...
Full textLink to itemCite
Journal ArticleHeart · April 2016
OBJECTIVE: Atrial fibrillation (AF) is a risk factor for stroke and mortality and the prothrombotic state has been linked to inflammation. In this study we evaluated the relationship between inflammatory biomarkers at baseline and future risk of cardiovasc ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2016
BACKGROUND: Adverse event collection in randomized clinical trials establishes drug safety. Although costly and regulated, it is rarely studied. METHODS: Adverse event data from 4 clinical trials (APPRAISE-2, PLATO, TRACER, TRILOGY ACS) comprising 48,118 p ...
Full textLink to itemCite
Journal ArticleBraz J Cardiovasc Surg · April 2016
INTRODUCTION: Antiplatelet therapy after coronary artery bypass graft (CABG) has been used. Little is known about the predictors and efficacy of clopidogrel in this scenario. OBJECTIVE: Identify predictors of clopidogrel following CABG. METHODS: We evaluat ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 22, 2016
BACKGROUND: Patients with acute coronary syndrome (ACS), especially those receiving medical management without revascularization, are at high risk for spontaneous myocardial infarction (MI), but its frequency and predictors are unknown. OBJECTIVES: This st ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · March 1, 2016
Monitoring anticoagulation using the activated clotting time (ACT) in patients treated with heparin and undergoing percutaneous coronary intervention (PCI) is one of the most frequently used tests in invasive cardiology. However, despite its widespread use ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2016
BACKGROUND: Among patients presenting with ST-segment elevation myocardial infarction (STEMI) for primary percutaneous coronary intervention (PCI), the associations between clinical outcomes and both baseline renal function and the development of acute kid ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2016
BACKGROUND: Although diabetes mellitus (DM) is a predictor of poor outcomes in patients with ST-segment elevation myocardial infarction (STEMI), few studies have analyzed the impact of DM on the constituency of coronary thrombi. OBJECTIVES: Comparing morph ...
Full textLink to itemCite
Journal ArticleLancet · January 23, 2016
BACKGROUND: REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. We tested the hypothesis that near complete inhibition of ...
Full textLink to itemCite
Journal ArticleCirculation · January 12, 2016
BACKGROUND: The internal mammary artery (IMA) is the preferred conduit for bypassing the left anterior descending (LAD) artery in patients undergoing coronary artery bypass grafting. Systematic evaluation of the frequency and predictors of IMA failure and ...
Full textLink to itemCite
ConferenceCardiovasc Revasc Med · 2016
BACKGROUND: Percutaneous coronary intervention (PCI) of saphenous vein grafts (SVG) poses a high-risk for distal coronary thromboembolic events. Glycoprotein IIb/IIIa inhibitors are frequently used in hope of reducing the impact of this, although the safet ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · January 1, 2016
BACKGROUND: Comorbid chronic obstructive pulmonary disease (COPD) is associated with poor outcomes among patients with cardiovascular disease. The risks of stroke and mortality associated with COPD among patients with atrial fibrillation are not well under ...
Full textLink to itemCite
Journal ArticlePLoS One · 2016
PURPOSE: Patients with acute myocardial infarction (AMI) and respiratory impairment may be treated with either invasive or non-invasive mechanical ventilation (MV). However, there has been little testing of non-invasive MV in the setting of AMI. Our object ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · January 2016
This guidance document focuses on the diagnosis and treatment of venous thromboembolism (VTE). Efficient, cost effective diagnosis of VTE is facilitated by combining medical history and physical examination with pre-test probability models, D dimer testing ...
Full textLink to itemCite
Journal ArticleEur Heart J · December 7, 2015
AIM: To assess clinical outcomes, efficacy, and safety according to sex during anticoagulation with apixaban compared with warfarin in patients with atrial fibrillation. METHODS AND RESULTS: Apixaban for Reduction in Stroke and Other Thromboembolic Events ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 1, 2015
BACKGROUND: Patients with atrial fibrillation (AF) and hypertension are at high risk for stroke. Previous studies have shown elevated risk of stroke in patients with AF who have a history of hypertension (regardless of blood pressure [BP] control) and in p ...
Full textLink to itemCite
Journal ArticleHeart · September 2015
OBJECTIVE: In the Apixaban for Prevention of Acute Ischemic Events (APPRAISE-2) trial, the use of apixaban, when compared with placebo, in high-risk patients with a recent acute coronary syndrome (ACS) resulted in a significant increase in bleeding without ...
Full textLink to itemCite
ConferenceCirculation · August 25, 2015
BACKGROUND: Apixaban is approved for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. However, the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial inc ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 18, 2015
BACKGROUND: Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). OBJECTIVES: We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. METHODS: This study examined ...
Full textLink to itemCite
Journal ArticleJ Am Coll Surg · August 2015
BACKGROUND: Hybrid coronary revascularization (HCR) combines minimally invasive left internal mammary artery to left anterior descending bypass with percutaneous coronary intervention of non-left anterior descending vessels. Its safety and effectiveness co ...
Full textLink to itemCite
Journal ArticleN Engl J Med · July 16, 2015
BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind st ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 18, 2015
BACKGROUND: Little is known about the incidence, predictors, or outcomes of intracranial hemorrhage (ICH) in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS). We aimed to determine the incidence and timing of ICH, characterize the ...
Full textLink to itemCite
Journal ArticleAm J Med · June 2015
BACKGROUND: Age is associated with outcomes in non-ST-segment elevation myocardial infarction; however, less is known about rehospitalization or death among elderly survivors. We aimed to evaluate mortality and cause-specific rehospitalization rates in thi ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2015
BACKGROUND: Elderly patients with ST-segment elevation myocardial infarction (STEMI) have worse outcomes and a greater risk of intracranial bleeding than nonelderly patients. Baseline characteristics, clinical outcomes, and the relationship of the tenectep ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · June 2015
OBJECTIVES: This study aimed to assess 6-month outcomes in patients with implantable cardioverter-defibrillators (ICDs) undergoing renal sympathetic denervation (RSD) for refractory ventricular arrhythmias (VAs). BACKGROUND: ICDs are generally indicated fo ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · June 2015
BACKGROUND: Heart failure (HF) is one of the leading causes of hospitalization in adults in Brazil. However, most of the available data is limited to unicenter registries. The BREATHE registry is the first to include a large sample of hospitalized patients ...
Full textLink to itemCite
Journal ArticleEur Heart J · May 21, 2015
AIM: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of stroke, major bleed, and death in patients with atrial fibrillation. In this ancillar ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2015
BACKGROUND: Hybrid coronary revascularization (HCR) combines a surgical and percutaneous approach for treatment of multivessel coronary artery disease. METHODS: A survey was conducted among 200 cardiologists and cardiac surgeons from 100 top-ranked US hosp ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2015
BACKGROUND: Clinical outcomes and the effects of oral anticoagulants among patients with acute coronary syndrome (ACS) and either a history of or acute heart failure (HF) are largely unknown. We aimed to assess the relationship between prior HF or acute HF ...
Full textLink to itemCite
Journal ArticleEur Heart J Cardiovasc Pharmacother · April 2015
AIMS: We compared clinical outcomes in patients with AF with and without diabetes in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. METHODS AND RESULTS: The main efficacy endpoints were SSE and mortality; ...
Full textLink to itemCite
Journal ArticleAm J Med · March 2015
BACKGROUND: Contemporary studies suggest an association between venous thromboembolism and a higher incidence of major cardiovascular events, mostly attributed to arterial atherothrombosis. Using data from the Nateglinide and Valsartan in Impaired Glucose ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2015
The novel oral anticoagulants (NOACs) have rapidly emerged as an alternative therapy to warfarin. Several recent phase 3 randomized control trials have demonstrated the efficacy and safety of the NOACs in the treatment for patients with nonvalvular atrial ...
Full textLink to itemCite
Journal ArticleClin Chem · February 2015
BACKGROUND: Although cardiac troponin is associated with outcomes in atrial fibrillation (AF), the complementary prognostic information provided by cardiac troponin I (cTnI) and cTnT is unknown. This study investigated the distribution, determinants, and p ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2015
BACKGROUND: The use of evidence-based therapies has improved the outcome of patients with acute coronary syndrome (ACS), but there is a time lag between the generation of clinical evidence and its application in routine clinical practice. We sought to quan ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2015
BACKGROUND: We sought to assess the occurrence of events after blinded study drug discontinuation and transition to open-label vitamin K antagonist (VKA) in ARISTOTLE. METHODS: At the end of ARISTOTLE, blinded study drug was stopped, and open-label VKA was ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2015
BACKGROUND: There is limited information about the association between diabetes, its treatment, and long-term angiographic and clinical outcomes in patients undergoing coronary artery bypass graft surgery (CABG). We evaluated the association of diabetes an ...
Full textLink to itemCite
Journal ArticleAnn Pharmacother · January 2015
Integration of accepted practice standards into electronic health record systems can facilitate standardization of anticoagulation care delivery and result in improved anticoagulation safety. However, the majority of commonly used electronic health record ...
Full textLink to itemCite
Journal ArticleInt J Gen Med · 2015
Atrial fibrillation (AF) is an important risk factor for thromboembolic events, and anticoagulation therapy can reduce this risk. Vitamin K antagonists (VKAs), such as warfarin, have been used for decades in patients with AF for stroke prevention. Currentl ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · December 20, 2014
BACKGROUND: Although the implantable cardioverter defibrillator (ICD) improves the survival of patients at increased risk of sudden cardiac death due to systolic heart failure, ICD shocks have been associated with both worse survival and quality of life. W ...
Full textLink to itemCite
Journal ArticleBlood · December 11, 2014
Using data from ARISTOTLE, we describe the periprocedural management of anticoagulation and rates of subsequent clinical outcomes among patients chronically anticoagulated with warfarin or apixaban. We recorded whether (and for how long) anticoagulant ther ...
Full textLink to itemCite
ConferenceJ Crit Care · December 2014
OBJECTIVE: Although hemodynamic monitoring is often performed after coronary artery bypass grafting (CABG), the role of monitoring postoperative central venous pressure (CVP) measurement as a predictor of clinical outcomes is unknown. As such, this study t ...
Full textLink to itemCite
Journal ArticleInteract Cardiovasc Thorac Surg · December 2014
OBJECTIVES: Cardiac ischaemic marker release is associated with adverse clinical outcomes after cardiac surgery. We sought to compare the release of cardiac troponin I (cTnI) after hybrid coronary revascularization (HCR) with off-pump coronary artery bypas ...
Full textLink to itemCite
Journal ArticleCirculation · November 18, 2014
BACKGROUND: Growth differentiation factor 15 (GDF-15), high-sensitivity troponin, and N-terminal pro-brain natriuretic peptide levels are predictive of death and cardiovascular events in healthy elderly subjects, patients with acute coronary syndrome, and ...
Full textLink to itemCite
Journal ArticleJ Thorac Cardiovasc Surg · November 2014
OBJECTIVE: To compare the outcomes between minimally invasive coronary artery bypass (MINI-CAB) and drug-eluting stent (DES) implantation for isolated left anterior descending artery disease. METHODS: Randomized and observational comparative publications w ...
Full textLink to itemCite
Journal ArticleCirculation · October 21, 2014
BACKGROUND: Coronary artery bypass grafting success is limited by vein graft failure (VGF). Understanding the factors associated with VGF may improve patient outcomes. METHODS AND RESULTS: We examined 1828 participants in the Project of Ex Vivo Vein Graft ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · October 14, 2014
BACKGROUND: Amiodarone is an effective medication in preventing atrial fibrillation (AF), but it interferes with the metabolism of warfarin. OBJECTIVES: This study sought to examine the association of major thrombotic clinical events and bleeding with the ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2014
BACKGROUND: Peak creatine kinase (CK)-MB concentration is related to reperfusion success and clinical outcomes after fibrinolytic therapy for acute myocardial infarction. However, prognostic implications of CK-MB measurements after primary percutaneous cor ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 15, 2014
Although a fibrinolytic pharmacoinvasive strategy is recommended for patients with ST elevation myocardial infarction (STEMI) unable to undergo timely primary percutaneous coronary intervention (PCI), there are limited data addressing outcomes specific to ...
Full textLink to itemCite
Journal ArticlePediatr Infect Dis J · September 2014
BACKGROUND: The epidemiology and incidence of late-onset blood stream infections (BSIs) in premature infants have been described, but studies describing late-onset BSI in term infants are sparse. We sought to describe the pathogens, incidence, risk factors ...
Full textLink to itemCite
Journal ArticleEuropace · September 2014
AIMS: Atrial fibrillation (AF) and coronary artery disease (CAD) are common in older patients. We aimed to describe the use of antiarrhythmic drug (AAD) therapy and clinical outcomes in these patients. METHODS AND RESULTS: We analysed AAD therapy and outco ...
Full textLink to itemCite
Journal ArticleJ Thromb Haemost · September 2014
BACKGROUND: D-dimer is related to adverse outcomes in arterial and venous thromboembolic diseases. OBJECTIVES: To evaluate the predictive value of D-dimer level for stroke, other cardiovascular events, and bleeds, in patients with atrial fibrillation (AF) ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2014
BACKGROUND: The perceived risk of serious bleeding is an obstacle to the use of oral anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with atrial fibrillation are unknown. METHODS: ARISTOTLE included 18,201 patients ...
Full textLink to itemCite
Journal ArticleClinics (Sao Paulo) · September 2014
OBJECTIVE: To describe the profile of physicians working at the Prehospital Emergency Medical System (SAMU) in Brazil and to evaluate their quality of life. METHODS: Both a semi-structured questionnaire with 57 questions and the SF-36 questionnaire were se ...
Full textLink to itemCite
Journal ArticleAnn Surg · August 2014
OBJECTIVE: To evaluate angiographic and clinical outcomes associated with open and closed dissection tunnel endoscopic vein harvesting (EVH) devices. BACKGROUND: A previous PREVENT-IV (PRoject of Ex-vivo Vein graft ENgineering via Transfection IV) analysis ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2014
BACKGROUND: Early termination of clinical trials due to low recruitment represents an understudied challenge for clinical research. We aimed to describe characteristics of cardiovascular trials terminated because of low recruitment and identify the major p ...
Full textLink to itemCite
Journal ArticleJAMA Surg · August 2014
IMPORTANCE: In vitro and animal model data suggest that intraoperative preservation solutions may influence endothelial function and vein graft failure (VGF) after coronary artery bypass graft (CABG) surgery. Clinical studies to validate these findings are ...
Full textLink to itemCite
Journal ArticleEur Heart J · July 21, 2014
AIMS: The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death, and bleeding. We evaluated these outcomes in relation to patient age. MET ...
Full textLink to itemCite
Journal ArticleCirculation · June 17, 2014
BACKGROUND: The optimal treatment for ischemic mitral regurgitation remains actively debated. Our objective was to evaluate the relationship between ischemic mitral regurgitation treatment strategy and survival. METHODS AND RESULTS: We retrospectively revi ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · June 3, 2014
BACKGROUND: The comparative effectiveness of treatments for atrial fibrillation (AF) is uncertain. PURPOSE: To evaluate the comparative effectiveness of rate- and rhythm-control therapies. DATA SOURCES: English-language studies in PubMed, EMBASE, and the C ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · May 27, 2014
OBJECTIVES: This study sought to characterize major bleeding on the basis of the components of the major bleeding definition, to explore major bleeding by location, to define 30-day mortality after a major bleeding event, and to identify factors associated ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2014
BACKGROUND: Hybrid coronary revascularization (HCR) represents a minimally invasive revascularization strategy in which the durability of the internal mammary artery to left anterior descending artery graft is combined with percutaneous coronary interventi ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · April 2014
Warfarin use in patients with acute myocardial infarction (AMI) and atrial fibrillation (AF) remains challenging. We describe use of warfarin up to 1 year after hospitalization among patients with AMI and AF according to stroke and bleeding risk, and ident ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 25, 2014
OBJECTIVES: The aim of this study was to determine the risk of major clinical and thromboembolic events after cardioversion for atrial fibrillation in subjects treated with apixaban, an oral factor Xa inhibitor, compared with warfarin. BACKGROUND: In patie ...
Full textLink to itemCite
Journal ArticleAnn Thorac Surg · March 2014
BACKGROUND: While extracardiac vascular disease (ECVD), defined as a history of peripheral vascular disease (PVD) or cerebrovascular disease (CBVD), is common in patients undergoing coronary artery bypass graft (CABG) surgery, there are limited data availa ...
Full textLink to itemCite
Journal ArticleCirculation · February 11, 2014
BACKGROUND: High-sensitivity troponin-I (hs-TnI) measurement improves risk assessment for cardiovascular events in many clinical settings, but the added value in atrial fibrillation patients has not been described. METHODS AND RESULTS: At randomization, hs ...
Full textLink to itemCite
Journal ArticleCrit Care Med · February 2014
OBJECTIVES: Guidelines recommend β-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outco ...
Full textLink to itemCite
ConferenceJ Am Coll Cardiol · January 7, 2014
OBJECTIVES: The aim of this study was to evaluate the prognostic value of high-sensitivity troponin T (hs-TnT) in addition to clinical risk factors and the CHA2DS2VASc (congestive heart failure, hypertension, 75 years of age and older, diabetes mellitus, p ...
Full textLink to itemCite
Journal ArticleThe American journal of cardiology · January 1, 2014
Although a fibrinolytic pharmacoinvasive strategy is recommended for patients with ST elevation myocardial infarction (STEMI) unable to undergo timely primary percutaneous coronary intervention (PCI), there are limited data addressing outcomes specific to ...
Cite
Journal ArticleEur Heart J · January 2014
AIMS: We assessed the effect of concomitant aspirin use on the efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation (AF). METHODS AND RESULTS: In ARISTOTLE, 18 201 patients were randomized to apixaban 5 mg twice daily ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · December 10, 2013
BACKGROUND: A substantial portion of patients with atrial fibrillation (AF) also have coronary artery disease (CAD) and are at risk for coronary events. Warfarin is known to reduce these events, but increase the risk of bleeding. We assessed the effects of ...
Full textLink to itemCite
Journal ArticleIntensive Care Med · December 2013
PURPOSE: Bleeding frequently complicates critical illness and may have serious consequences. Our objectives are to describe the predictors of major bleeding and the association between bleeding and mortality in medical-surgical critically ill patients rece ...
Full textLink to itemCite
Journal ArticleClinics (Sao Paulo) · December 2013
OBJECTIVES: To correlate the importance of the ankle-brachial index in terms of cardiovascular morbimortality and the extent of coronary arterial disease amongst elderly patients without clinical manifestations of lower limb peripheral arterial disease. ME ...
Full textLink to itemCite
Journal ArticleAnn Thorac Surg · December 2013
Hybrid coronary revascularization (HCR) combines bypass grafting of the left anterior descending (LAD) coronary artery with percutaneous coronary intervention (PCI) of non-LAD vessels. HCR has been performed as an alternative to CABG or multi-vessel PCI in ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · November 2013
Dual antiplatelet therapy with both aspirin and clopidogrel is increasingly used after coronary artery bypass grafting (CABG); however, little is known about the safety or efficacy. We sought to determine the relationship between postoperative clopidogrel ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2013
BACKGROUND: Left ventricular end-diastolic pressure (LVEDP) is frequently measured during primary percutaneous coronary intervention (PCI). However, little is known of this measurement's utility in predicting outcomes or informing treatment decisions. We s ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2013
BACKGROUND: We sought to determine the risk of readmission for bleeding and major cardiac events in stented non-ST-segment elevation myocardial infarction (NSTEMI) atrial fibrillation (AF) patients. METHODS: For this patient population, selection of an ant ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 1, 2013
Atrial fibrillation (AF) is an independent predictor of mortality after acute myocardial infarction (AMI). We analyzed the relation between biomarkers linked to myocardial stretch (NT-pro-brain natriuretic peptide [NT-proBNP]), myocardial damage (Troponin- ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · October 3, 2013
BACKGROUND: Plaque rupture, acute ischemia, and necrosis in acute coronary syndromes are accompanied by concurrent pro- and anti-inflammatory cascades. Whether STEMI clinical prediction models can be improved with the addition of baseline inflammatory biom ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · October 3, 2013
BACKGROUND: We assessed the incidence and timing of post-acute coronary syndrome (ACS) atrial fibrillation (AF) related and not related to coronary artery bypass grafting (CABG); described the use of antithrombotic therapy; and evaluated the association of ...
Full textLink to itemCite
Journal ArticleInt J Stroke · October 2013
The availability of population-based epidemiological data on the incident risk of stroke is very scarce in Argentina and other Latin American countries. In response to the priorities established by the World Health Organization and the United Nations, PREV ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · September 10, 2013
BACKGROUND: Elderly patients with acute coronary syndromes (ACS) are at high risk for death and recurrent thrombotic events. We evaluated the efficacy and safety of intensive treatment with glycoprotein IIb/IIIa inhibitors in an elderly population, and the ...
Full textLink to itemCite
Journal ArticleExpert Rev Cardiovasc Ther · September 2013
Atrial fibrillation (AF) is associated with significant mortality and morbidity, and stroke represents the most-feared complication. Consequently, AF treatment has focused on thromboprophylaxis, with warfarin as the mainstay of therapy. However, concerns o ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2013
BACKGROUND: Patients with atrial fibrillation who are vitamin K antagonist (VKA)-naive may have a higher risk of thrombosis and/or bleeding than VKA-experienced patients. METHODS AND RESULTS: Using data from ARISTOTLE, we assessed baseline characteristics ...
Full textLink to itemCite
Journal ArticleCirculation · August 13, 2013
BACKGROUND: The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear. We assessed concomitant ASA use and its association with clinical outcomes among AF patients treated with O ...
Full textLink to itemCite
Journal ArticleEur Heart J · August 2013
AIMS: It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF). METHODS AND RESULTS: A total of 18 201 patients with AF [2786 (15.3%) with paroxysmal and 15 412 (84.7%) with persistent or permanent] were ran ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2013
BACKGROUND: In 2010, after regulatory review of rosiglitazone licensing, the US Food and Drug Administration (FDA) requested a reevaluation of cardiovascular end points in the RECORD trial. METHODS: Automated screening of the original clinical trial databa ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2013
BACKGROUND: The US Food and Drug Administration (FDA) required a reevaluation of cardiovascular (CV) outcomes in the RECORD trial. This provided an opportunity to assess the implications of event adjudication by 2 groups and quantify the differences as wel ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · July 2013
To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Fifth International Symposium of Thrombosis and Anticoagulation was held in Belo Horizonte, Minas Gerais, Brazil, on October 18-19, 2012. This scientific p ...
Full textLink to itemCite
Journal ArticleExpert Opin Drug Saf · July 2013
INTRODUCTION: Traditional oral anticoagulants, such as warfarin, are effective but require frequent laboratory monitoring for dose adjustment and have several known interactions with food and other drugs. Oral direct factor Xa inhibitors are an emerging cl ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · July 2013
BACKGROUND: Patients with atrial fibrillation (AF) at the highest stroke risk derive the largest benefit from oral anticoagulation (OAC). Those with the highest stroke risk have been paradoxically less likely to receive OAC. This study assessed the associa ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 4, 2013
OBJECTIVES: This study sought to assess the prognostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with atrial fibrillation (AF) enrolled in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrill ...
Full textLink to itemCite
Journal ArticleCirculation · June 4, 2013
BACKGROUND: In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effect ...
Full textLink to itemCite
Journal ArticleCoron Artery Dis · June 2013
OBJECTIVES: Using data from the CHAMPION percutaneous coronary intervention (PCI), we determined the relationship between clopidogrel started at least 5 days before PCI (maintenance of clopidogrel) and PCI-related enzymatic infarct size. BACKGROUND: Clopid ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2013
In recent years, international clinical trials have increasingly included large numbers of patients and research sites from developing countries. In South America particularly, enrollment in randomized clinical trials has increased substantially. Despite t ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2013
BACKGROUND: We examined the prevalence of undiagnosed diabetes or prediabetes and associations with ischemic outcomes among non-ST-segment elevation acute coronary syndrome (ACS) patients. METHODS: We categorized 8795 EARLY ACS trial patients into one of t ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · June 2013
OBJECTIVES: This study sought to describe the occurrence and timing of heart failure (HF), associated clinical factors, and 30-day outcomes in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). BACKGROUND: Little is known about HF- ...
Full textLink to itemCite
Journal ArticleTrials · May 2, 2013
BACKGROUND: Larger infarct size measured by creatine kinase (CK)-MB release is associated with higher mortality and has been used as an important surrogate endpoint in the evaluation of new treatments for ST-segment elevation myocardial infarction (STEMI). ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Heart Fail · May 2013
BACKGROUND: We examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARI ...
Full textLink to itemCite
Journal ArticleAnn Surg · May 2013
OBJECTIVE: To review our current understanding of the epidemiology and pathogenesis of vein graft failure (VGF), give an overview of current preventive and interventional measures, and explore strategies that may improve vein graft patency. BACKGROUND: VGF ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2013
Saphenous vein graft (SVG) failure is a common finding in patients following coronary artery bypass graft (CABG) surgery. In the literature SVG failure rates have been reported from 25 to over 50% within 10 years. Although common, it remains unclear to wha ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · April 2013
BACKGROUND: Stroke is a rare but potentially devastating complication of acute myocardial infarction. Little is known about stroke timing, characteristics, and clinical outcomes in patients with ST-segment elevation myocardial infarction treated with prima ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · March 2013
BACKGROUND: Data on outpatient care provided to patients at high cardiovascular risk in Brazil are insufficient. OBJECTIVE: To describe the profile and document the clinical practice of outpatient care in patients at high cardiovascular risk in Brazil, reg ...
Full textLink to itemCite
Journal ArticlePostgrad Med · March 2013
Stroke is the most feared complication among patients with atrial fibrillation. Oral anticoagulation therapy with vitamin K antagonists (VKAs) has been the gold standard for stroke prevention for the past 60 years. However, VKA therapy has many downsides, ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · January 15, 2013
Antiplatelet therapy is recommended after coronary artery bypass grafting, because it improves saphenous vein graft (SVG) patency and clinical outcomes. We investigated the association between prehospital antiplatelet regimens and outcomes after SVG interv ...
Full textLink to itemCite
Journal ArticleJ Nephrol · 2013
BACKGROUND: The relationship between renal dysfunction and mortality after myocardial infarction (MI) has been demonstrated in patients with reduced ejection fraction. The importance of diastolic dysfunction in this scenario is unknown. METHODS: We studied ...
Full textLink to itemCite
Journal ArticleHellenic J Cardiol · 2013
INTRODUCTION: Abnormal ventricular repolarization has been proposed as a marker of arrhythmogenesis, and cardiovascular morbidity and mortality. However, little is known about the influence of the interval between the peak and the end of the T wave (Tp-Te) ...
Link to itemCite
Journal ArticleRevista Brasileira de Cardiologia Invasiva · January 1, 2013
Background: Catheter-based renal sympathetic denervation has emerged as an adjunct strategy to control refractory hypertension. No studies have yet compared the tissue effects of different catheters, powers and time periods of radiofrequency application, w ...
Full textCite
Journal ArticleJ Am Coll Cardiol · December 4, 2012
OBJECTIVES: This study compared prognoses of myocardial infarction related to percutaneous coronary intervention (PCI, procedural MI) using increasing creatine kinase-myocardial band (CK-MB) thresholds with spontaneous MI. BACKGROUND: Procedural MI usually ...
Full textLink to itemCite
Journal ArticleLancet · November 17, 2012
BACKGROUND: The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at prevention of stroke or systemic embolism, causes less bleeding, and results in lower ...
Full textLink to itemCite
Journal ArticleAm J Med · November 2012
PURPOSE: Substantial heterogeneity in hospital length of stay exists among patients admitted with non-ST-segment elevation myocardial infarction. Furthermore, little is known about the factors that impact length of stay. METHODS: We examined 39,107 non-ST- ...
Full textLink to itemCite
Journal ArticleEur Heart J · November 2012
AIMS: Atrial fibrillation (AF) is common among patients with impaired renal function. Apixaban, a novel oral anticoagulant with partial renal excretion, was compared with warfarin and reduced the rate stroke, death and bleeding in the ARISTOTLE trial. We e ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · November 2012
Heparin-induced thrombocytopenia (HIT) is a clinicopathologic syndrome initiated by heparin exposure and characterized by thrombocytopenia and paradoxical thrombophilia. HIT is mediated by the formation of antibodies against the platelet factor 4/heparin c ...
Full textLink to itemCite
Journal ArticleN Engl J Med · October 4, 2012
BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2012
BACKGROUND: Older patients with atrial fibrillation (AF) and coronary artery disease (CAD) face high risk of stroke and bleeding with antithrombotic therapy. Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is impor ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · October 2012
Coronary artery embolism is an uncommon cause of myocardial infarction. We report a case of acute ST-segment elevation myocardial infarction due to a coronary embolism that originated from a calcified aortic valve. Coronary angiography demonstrated complet ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2012
BACKGROUND: Aspiration thrombectomy is used in primary percutaneous coronary interventions, but the importance of thrombus constituency has been scarcely investigated. The objective of this study was to evaluate thrombus constituency and its association wi ...
Full textLink to itemCite
Journal ArticleAm J Med · September 2012
BACKGROUND: Atrial fibrillation guidelines recommend long-term use of warfarin according to a patient's predicted risk of stroke. After acute myocardial infarction, however, combining warfarin and antiplatelet medications poses challenges. METHODS: By usin ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2012
BACKGROUND: Edifoligide, an E2F transcription factor decoy, does not prevent vein graft failure or adverse clinical outcomes at 1 year in patients undergoing coronary artery bypass grafting (CABG). We compared the 5-year clinical outcomes of patients in PR ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · September 1, 2012
BACKGROUND: Elderly patients with acute coronary syndrome are at high risk of recurrent ischemic events and death, and for both antithrombotic therapy and catheter-based complications. This prespecified analysis investigates the effect and treatment-relate ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · September 2012
OBJECTIVES: The authors sought to describe the association between post-procedural bleeding and long-term recurrent bleeding, major adverse cardiac events (MACE), and mortality among older patients undergoing percutaneous coronary intervention (PCI). BACKG ...
Full textLink to itemCite
Journal ArticleTrials · August 28, 2012
BACKGROUND: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with A ...
Full textLink to itemCite
Journal ArticleEur Heart J · August 2012
AIMS: Bleeding complications have been associated with short-term mortality in patients with non-ST-segment elevation myocardial infarction (NSTEMI). Their association with long-term outcomes is less clear. This study examines mortality associated with in- ...
Full textLink to itemCite
Journal ArticleJAMA · August 1, 2012
CONTEXT: The safety and durability of endoscopic vein graft harvest in coronary artery bypass graft (CABG) surgery has recently been called into question. OBJECTIVE: To compare the long-term outcomes of endoscopic vs open vein-graft harvesting for Medicare ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · July 2012
To discuss and share knowledge about advances in the care of patients with thrombotic disorders, the Fourth International Symposium of Thrombosis and Anticoagulation was held in Salvador, Bahia, Brazil, from October 20-21, 2011. This scientific program was ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · July 2012
OBJECTIVES: The aim of this study was to address the knowledge gap using the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infarction) trial database. We also assessed the association between serious infections and 90-day death or death/myocardia ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · July 1, 2012
BACKGROUND: Transfer delays for primary percutaneous coronary intervention may increase mortality in patients with ST-segment-elevation myocardial infarction. We examined the association between door 1-to-door 2 (D1D2) time, a measure capturing the entire ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · July 2012
Coronary plaque rupture is associated with a systemic inflammatory response. The relationship between baseline N-terminal pro B-type natriuretic peptide (NT-proBNP), a prognostic marker in patients with acute coronary syndromes, and systemic inflammatory m ...
Full textLink to itemCite
Journal ArticleCirculation · June 12, 2012
BACKGROUND: Patients with acute coronary syndromes and history of stroke or transient ischemic attack (TIA) have an increased rate of recurrent cardiac events and intracranial hemorrhages. METHODS AND RESULTS: We evaluated treatment effects of ticagrelor v ...
Full textLink to itemCite
Journal ArticleLancet Neurol · June 2012
BACKGROUND: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk ...
Full textLink to itemCite
Journal ArticleRev Esp Cardiol (Engl Ed) · June 2012
INTRODUCTION AND OBJECTIVES: Chagas disease is a prevalent cause of heart failure in Latin America, and its prognosis is worse than other etiologies. The Heart Failure Survival Score has been used to assess prognosis in patients with heart failure; however ...
Full textLink to itemCite
Journal ArticleJAMA · May 16, 2012
CONTEXT: Studies have found that patients with acute coronary syndromes (ACS) often do not receive evidence-based therapies in community practice. This is particularly true in low- and middle-income countries. OBJECTIVE: To evaluate whether a multifaceted ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2012
BACKGROUND: Information on practice patterns and outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary interventions (PCIs) in Canada vs United States is limited. METHODS: We evaluated differences in clinical ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2012
BACKGROUND: We sought to characterize patient factors and regional variations associated with vitamin K antagonist (VKA) use in patients with heart failure (HF) and atrial fibrillation (AF) in areas outside the United States and Europe. METHODS: The ADHERE ...
Full textLink to itemCite
Journal ArticleJ Heart Valve Dis · May 2012
BACKGROUND AND AIM OF THE STUDY: The natriuretic peptides, brain natriuretic peptide (BNP) and its N-terminal prohormone (NT-proBNP), can be used as diagnostic and prognostic markers for aortic stenosis (AS). However, the association between BNP, NT-proBNP ...
Link to itemCite
Journal ArticleAm Heart J · April 2012
BACKGROUND: We aimed to study the comparative safety and effectiveness of various antithrombotic treatment strategies among older adults with non-ST elevation myocardial infarction (NSTEMI) and atrial fibrillation (AF). METHODS: Using the CRUSADE registry ...
Full textLink to itemCite
Journal ArticleCirculation · March 20, 2012
BACKGROUND: Non-ST-segment-elevation myocardial infarction patients on home warfarin pose treatment concerns because of their potential increased risk of bleeding. Expert opinion from the American College of Cardiology/American Heart Association guidelines ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2012
Translating evidence into clinical practice in the management of acute coronary syndromes (ACS) is challenging. Few ACS quality improvement interventions have been rigorously evaluated to determine their impact on patient care and clinical outcomes. We des ...
Full textLink to itemCite
Journal ArticleExpert Rev Cardiovasc Ther · March 2012
Atrial fibrillation (AF), gastroesophageal reflux disease (GERD) and hiatal hernias are commonly seen in clinical practice. GERD and hiatal hernias have been proposed to be a possible cause of AF. In this paper, we will briefly review GERD, AF and hiatal h ...
Full textLink to itemCite
Journal ArticleCirculation · February 14, 2012
BACKGROUND: Vein graft failure (VGF) is common after coronary artery bypass graft surgery, but its relationship with long-term clinical outcomes is unknown. In this retrospective analysis, we examined the relationship between VGF, assessed by coronary angi ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · February 2012
Randomized clinical trials have conclusively demonstrated that warfarin prevents stroke in patients with atrial fibrillation. This evidence led the American College of Cardiology, the American Heart Association, and the European Society of Cardiology to de ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · February 1, 2012
Gender-related differences in the incidence of bleeding and its relation to subsequent mortality in patients with ST-segment elevation myocardial infarction (STEMI) treated with fibrinolysis are not well understood. We studied patients with STEMI receiving ...
Full textLink to itemCite
Journal ArticleJAMA · January 4, 2012
CONTEXT: ST-segment elevation myocardial infarction (STEMI) treatment has improved outcomes and shortened hospital stay. Recently, 30-day readmission rates have been proposed as a metric for care of patients with STEMI. However, international rates and pre ...
Full textLink to itemCite
Journal ArticleBlood · December 8, 2011
Ms TS is a 66-year-old woman who receives warfarin for prevention of systemic embolization in the setting of hypertension, diabetes, and atrial fibrillation. She had a transient ischemic attack about 4 years ago when she was receiving aspirin. Her INR cont ...
Full textLink to itemCite
Journal ArticleStroke · December 2011
BACKGROUND AND PURPOSE: Current American Heart Association/American Stroke Association guidelines identify warfarin use as a class IA indication in patients with atrial fibrillation (AF) and ischemic stroke (IS) or transient ischemic attack (TIA). However, ...
Full textLink to itemCite
Journal ArticleAcute Coronary Syndromes · November 17, 2011
Atrial fibrillation (AF) is the most commonly encountered cardiac arrhythmia in clinical practice. Furthermore, the incidence of AF steadily increases with advancing age, and AF is also a frequently diagnosed complication following ACS. The management of p ...
Cite
Journal ArticleAm J Med · November 2011
PURPOSE: We sought to assess the effect of naproxen versus placebo on prevention of atrial fibrillation after coronary artery bypass graft (CABG) surgery. METHODS: In this randomized, double-blind, placebo-controlled, single-center trial of 161 consecutive ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2011
BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with an increased risk of stroke, heart failure, and death. Data on contemporary treatment patterns and outcomes associated with AF in clinical practice ...
Full textLink to itemCite
Journal ArticleN Engl J Med · September 15, 2011
BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 15, 2011
We compared the clinical features, laboratory and coronary angiographic findings, treatments, and outcomes among patients with ST-segment elevation myocardial infarction (MI) with and without left bundle branch block (LBBB). We examined 5,742 patients with ...
Full textLink to itemCite
Journal ArticleCirculation · September 13, 2011
BACKGROUND: Some prior studies have suggested that the time to cardiac surgery after cardiac catheterization is inversely related to postoperative acute kidney injury (AKI). However, these studies, because of the small number of patients, were unable to ad ...
Full textLink to itemCite
Journal ArticleN Engl J Med · August 25, 2011
BACKGROUND: Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. METHODS: We conducted a randomized, double-blind, placebo-controlled clinical t ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · August 2011
To discuss and share knowledge around advances in the care of patients with thrombotic disorders, the Third International Symposium of Thrombosis and Anticoagulation was held in São Paulo, Brazil, from October 14-16, 2010. This scientific program was devel ...
Full textLink to itemCite
Journal ArticleCirculation · July 19, 2011
BACKGROUND: Limited information exists on the intermediate-term graft patency and 5-year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus single distal targets (s-SVG) during coronary artery bypass graft (CABG) sur ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · May 2011
Patients with prosthetic heart valves require chronic oral anticoagulation. In this clinical scenario, physicians must be mindful of the thromboembolic and bleeding risks related to chronic anticoagulant therapy. Currently, only vitamin K antagonists are a ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · April 2011
Despite improvements in the treatment of acute coronary syndromes (ACS), cardiovascular disease remains the leading cause of death in the United States. Antiplatelet agents, such as aspirin and clopidogrel, play an important role in the treatment of patien ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2011
BACKGROUND: The association of sustained ventricular tachycardia/fibrillation (VT/VF) with mortality in patients undergoing primary percutaneous coronary intervention (PCI) may vary with baseline patient risk and may be associated with higher mortality in ...
Full textLink to itemCite
Journal ArticleArch Intern Med · March 28, 2011
BACKGROUND: To understand the influence of age on treatment and outcomes, we analyzed the largest group of patients 75 years or older with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention (PPCI) in a clinic ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · March 1, 2011
We sought to identify patients at risk for premature discontinuation of thienopyridines and to develop a risk score for thienopyridine adherence after coronary stent implantation. Patients were prospectively included from December 2007 to March 2008. At 1- ...
Full textLink to itemCite
Journal ArticleAm J Med · January 2011
BACKGROUND: studies have shown higher bleeding and mortality rates among African Americans who receive fibrinolytic therapy for ST-segment elevation myocardial infarction (STEMI) compared with whites; however, the relationship of bleeding risk to mortality ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · January 2011
Venous thromboembolism is a major cause of morbidity and mortality worldwide and most often affects hospitalized postoperative surgical and medical patients. Venous thromboembolism prophylaxis undoubtedly improves the care of these patients, as demonstrate ...
Full textLink to itemCite
Journal ArticleClinics (Sao Paulo) · 2011
OBJECTIVES: N-3 polyunsaturated fatty acids have been proposed as a novel treatment for preventing postoperative atrial fibrillation due to their potential anti-inflammatory and anti-arrhythmic effects. However, randomized studies have yielded conflicting ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · December 15, 2010
Whether prognosis differs in acute renal failure (ARF) after coronary artery bypass grafting (CABG) in patients with and without recovery of renal function is not known. We studied patients who had CABG at Duke University Medical Center (1995 to 2008). ARF ...
Full textLink to itemCite
Journal ArticleThromb Haemost · December 2010
Atrial fibrillation is a common condition that increases the risk of stroke in many patients. Although warfarin has been shown to reduce the risk of stroke, many patients who might benefit from anticoagulation do not receive this therapy. Fear of bleeding ...
Full textLink to itemCite
Journal ArticleAm Heart J · December 2010
BACKGROUND: Major bleeding during an acute coronary syndrome (ACS) is associated with increased late ischemic events. Patients with bleeding are often discharged without antiplatelet therapy (AT). The association between discharge AT use and late ischemic ...
Full textLink to itemCite
Journal ArticleCardiovasc Ther · October 2010
Surgical or modified Maze procedures have been promoted to treat atrial fibrillation (AF); however, few randomized controlled clinical trials (RCTs) examine their outcomes. The purpose of this meta-analysis is to compare the efficacy of surgical Maze proce ...
Full textLink to itemCite
Journal ArticleRev Bras Ter Intensiva · September 2010
Trauma is the leading cause of death in people below 45 years-old in Brazil, and responsible for one third of all intensive care unit admissions. The increasing knowledge on ultrasound diagnosis methods and its availability for life-threatening injuries (s ...
Full textLink to itemCite
Journal ArticleCurr Opin Cardiol · July 2010
PURPOSE OF REVIEW: Prevention of stroke and systemic emboli is paramount in the management of atrial fibrillation. Although warfarin is the predominant anticoagulant used in patients with atrial fibrillation, it has significant limitations that have impede ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · June 2010
OBJECTIVES: The aim of this study was to examine the use of and outcomes associated with antithrombotic strategies in patients with non-ST-segment elevation myocardial infarction (NSTEMI) who undergo percutaneous coronary intervention (PCI). BACKGROUND: A ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · May 2010
The use of anticoagulant and antiplatelet therapy during the management of acute coronary syndromes (ACS) has been associated with improvements in short- and long-term clinical outcomes, regardless of whether patients are managed conservatively or with acu ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · April 2010
Acute ischemic stroke is the result of abrupt interruption of focal cerebral blood flow. The majority of ischemic strokes are caused by embolic or thrombotic arterial occlusions. Acute stroke management is complex, in part because of the varying etiologies ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2010
Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high incidence of complications when patients' international normalized rati ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · March 2010
BACKGROUND: Recent studies show that the expression of inflammatory mediators, such as cytokines, is an important factor for the development and progression of heart failure (HF), especially in the presence of left ventricular dysfunction. These changes ha ...
Full textLink to itemCite
Journal ArticleAm J Med · February 2010
BACKGROUND: We examined warfarin use at discharge (according to Congestive heart failure, Hypertension, Age>75 years, Diabetes, Prior Stroke/transient ischemic attack score and bleeding risk) and its association with 6-month death or myocardial infarction ...
Full textLink to itemCite
Journal ArticleJ Electrocardiol · 2010
BACKGROUND: Atrial infarction reportedly occurs in 0.7% to 52% of ST-elevation myocardial infarctions (STEMIs), up to two thirds of whom develop atrial fibrillation and flutter (AF). Prospective validation of electrocardiographic atrial infarction patterns ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2010
BACKGROUND: Despite advances in treatment of cardiogenic shock (CS), the incidence of this serious complication of acute ST-elevation myocardial infarction (STEMI) has stayed relatively constant, and rates of mortality, although somewhat improved in recent ...
Full textLink to itemCite
Journal ArticleCytokine · January 2010
Heart failure (HF) is associated with changes in the skeletal muscle (SM) which might be a consequence of the unbalanced local expression of pro- (TNF-alpha) and anti- (IL-10) inflammatory cytokines, leading to inflammation-induced myopathy, and SM wasting ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · December 2009
Over the past 50 years, the understanding of the deteriorative changes involved in the progression of heart failure (HF), initially described as resulting from changes in salt and fluid retention, or changes in hemodynamic parameters, have changed signific ...
Link to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · December 2009
BACKGROUND: Catheter ablation is an established yet evolving nonpharmacologic intervention for the maintenance of sinus rhythm in patients with atrial fibrillation (AF). The efficacy and safety of pulmonary vein isolation (PVI) compared with medical therap ...
Full textLink to itemCite
Journal ArticleAcute Coronary Syndromes · December 1, 2009
It has been >20 years since the double-blind BHAT (β-Blocker Heart Attack Trial) showed that the β-blocker propranolol reduced the rate of mortality when initiated in the first week following myocardial infarction (MI). Despite an overall 23% reduction in ...
Cite
Journal ArticleArquivos Brasileiros de Cardiologia · December 1, 2009
Over the past 50 years, the understanding of the deteriorative changes involved in the progression of heart failure (HF), initially described as resulting from changes in salt and fluid retention, or changes in hemodynamic parameters, have changed signific ...
Cite
Journal ArticleAm J Cardiol · November 1, 2009
Thrombocytopenia is a predictor of adverse outcomes in patients with acute coronary syndromes and in critically ill patients. The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry was designed to explore the incidence, management, and ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · October 2009
Venous thromboembolism is a major cause of morbidity and mortality affecting over 2 million people in the United States each year. The American College of Chest Physicians (ACCP) published their first consensus statement on antithrombotic therapy in 1986, ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 7, 2009
Antiplatelet agents play an important role in the treatment of non-ST-segment elevation acute coronary syndromes (NSTE ACS), particularly for those at high risk, such as older adults (aged > or =75 years) where treatment may yield the greatest benefits. Pa ...
Full textLink to itemCite
Journal ArticleEur Heart J · August 2009
AIMS: To assess the incidence and timing of atrial fibrillation (AF), describe antithrombotic therapy use, and evaluate the association of AF with 90 day mortality and other secondary clinical outcomes. METHODS AND RESULTS: We studied 5745 ST-segment eleva ...
Full textLink to itemCite
Journal ArticleN Engl J Med · July 16, 2009
BACKGROUND: Vein-graft harvesting with the use of endoscopy (endoscopic harvesting) is a technique that is widely used to reduce postoperative wound complications after coronary-artery bypass grafting (CABG), but the long-term effects on the rate of vein-g ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · July 2009
The importance of thrombosis and anticoagulation in clinical practice is rooted firmly in several fundamental constructs that can be applied both broadly and globally. Awareness and the appropriate use of anticoagulant therapy remain the keys to prevention ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · July 2009
The perioperative management of patients taking vitamin K antagonists (VKAs) is an evolving area of medicine and poses significant challenges for health care providers. It has been estimated that this issue affects approximately 250,000 patients annually, ...
Full textLink to itemCite
Journal ArticleJAMA · May 6, 2009
CONTEXT: The incidence and timing of sustained ventricular tachycardia or fibrillation (VT/VF) and its impact on outcomes in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) are poorly und ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 24, 2009
OBJECTIVES: This study sought to evaluate the impact of age on outcomes in patients with moderate- and high-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) enrolled in the ACUITY (Acute Catheterization and Urgent Intervention Triage Strate ...
Full textLink to itemCite
Journal ArticleRev Bras Ter Intensiva · March 2009
Cardiac arrest survivors frequently suffer from ischemic brain injury associated with poor neurological outcome and death. Therapeutic hypothermia improves outcomes in comatose survivors after resuscitation from out-of-hospital cardiac arrest. Considering ...
Link to itemCite
Journal ArticleCell Biochem Funct · March 2009
The paraneoplastic syndrome of cachexia is considered a degenerative chronic inflammatory disease, being deeply related to the increase of pro-inflammatory factors, especially tumour necrosis factor alpha (TNF-alpha). It is known that the adipose tissue is ...
Full textLink to itemCite
Journal ArticleJournal of medical case reports · January 2009
IntroductionBilateral macular hemorrhage is a rare ocular finding and to the best of our knowledge, this is the first report of such hemorrhages as a presentation of drug-induced anemia.Case presentationWe describe the case of a 14-year-o ...
Full textCite
Journal ArticleJ Thromb Thrombolysis · December 2008
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice, accounting for approximately one-third of hospitalizations for cardiac rhythm disturbances. The highest incidence of AF is in patients 70-80 years old and other high-risk ...
Full textLink to itemCite
Journal ArticleEur Heart J · August 2008
AIMS: Elderly patients are at high risk from non-ST-segment elevation acute coronary syndromes (NSTE ACS) as well as from treatment-related complications. Age-associated changes in physiology may alter the risk and benefit expected from therapy. The SYNERG ...
Full textLink to itemCite
Journal ArticleHeart · July 2008
OBJECTIVE: To assess variables associated with the occurrence of atrial fibrillation (AF) and the relation of AF with short- and long-term outcomes and with other in-hospital complications in patients with acute coronary syndromes (ACS) with and without ST ...
Full textLink to itemCite
Journal ArticleDermatol Online J · June 15, 2008
We report a case of a 55-year-old man who, after a 6-month history of enlargement of cervical lymph nodes, presented with multiple painful ulcerations of the oral mucosa and lips and multiple skin erosions on the trunk, back, extremities, and genitals. A l ...
Link to itemCite
Journal ArticleMed Sci Sports Exerc · March 2008
PURPOSE: Exercise training restores innate immune system cell function in post-myocardial infarction (post-MI) rats. However, studies of the involvement of lymphocyte (Ly) in the setting of the congestive heart failure (CHF) are few. To address this issue, ...
Full textLink to itemCite
Journal ArticleCurr Cardiol Rep · September 2007
Accomplishing a successful percutaneous coronary intervention in a patient with a suspected or diagnosed heparin-induced thrombocytopenia (HIT) requires the selection of an appropriate alternative anticoagulant and a thorough assessment of bleeding and thr ...
Full textLink to itemCite
Journal ArticleArq Bras Cardiol · April 2007
OBJECTIVES: To determine the plasma homocysteine and von Willebrand factor levels as markers of endothelial dysfunction in rats with diabetes mellitus induced by streptozotocin. METHODS: Thirty-five adult male rats (Rattus norvegicus albinus) (weight betwe ...
Full textLink to itemCite
Journal ArticleArquivos Brasileiros de Cardiologia · 2007
Objectives: To determine the plasma homocysteine and von Willebrand factor levels as markers of endothelial dysfunction in rats with diabetes mellitus induced by streptozotocin. Methods: Thirty-five adult male rats (Rattus norvegicus albinus) (weight betwe ...
Cite
Journal ArticleConf Proc IEEE Eng Med Biol Soc · 2006
This article discusses a telemedicine model for emerging countries, through the description of ONCONET, a telemedicine initiative applied to pediatric oncology in Brazil. The ONCONET core technology is a Web-based system that offers health information and ...
Full textLink to itemCite
Journal ArticleBMC Public Health · November 10, 2005
BACKGROUND: Helicobacter pylori (Hp) infection is associated with several upper gastrointestinal disorders. Local data on the epidemiology of the infection are scarce in Brazil. The purpose of this study is to measure the prevalence rate and to explore the ...
Full textLink to itemCite
Journal ArticleStud Health Technol Inform · 2001
Only recently, advanced direct volume visualization techniques have been widely used due to the availability of low cost hardware accelerators; such techniques have a great potential of use for many applications of the virtual reality in medicine. We propo ...
Link to itemCite
Journal ArticleStud Health Technol Inform · 2001
Bone marrow transplant is a relatively new procedure to treat recently considered incurable diseases. One important part of the procedure is the process of harvesting the donor bone marrow. We are developing a virtual reality simulator for bone marrow harv ...
Link to itemCite
Journal ArticleRev Assoc Med Bras (1992) · 1999
PURPOSE: In the present study we evaluated, by light microscopy, and throughout morphometry, whether hypertrophy of cardiac striated muscular fibers of left ventricular occur in albino rat, during pregnancy. METHODS: After maiting, 12 nuliparous rats were ...
Full textLink to itemCite